Browse by Research Team

2024

HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation.
Welters, C. and Welters, M.L. and Stadler, S. and Bullinger, L. and Strobel, J. and Hackstein, H. and Dhamodaran, A. and Blankenstein, T. and Hansmann, L.
Haematologica 109 (4): 1121-1127. April 2024

Oligonucleotide library screening for identification of virus-specific T-cell receptors.
Welters, M.L. and Stadler, S. and Anastasopoulou, V. and Bullinger, L. and Leisegang, M. and Kammertöns, T. and Welters, C. and Hansmann, L.
European Journal of Immunology : e2350908. 19 March 2024 (In Press)

Comparable CD8(+) T-cell responses to SARS-CoV-2 vaccination in single-cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.
Tranter, Eva and Frentsch, Marco and Hütter-Krönke, Marie Luise and Vuong, Giang Lam and Busch, David and Loyal, Lucie and Henze, Larissa and Rosnev, Stanislav and Blau, Igor-Wolfgang and Thiel, Andreas and Beule, D. and Bullinger, L. and Obermayer, B. and Na, I.K.
Journal of medical virology 96 (3): e29539. March 2024

Covering hierarchical dirichlet mixture models on binary data to enhance genomic stratifications in onco-hematology.
Dall'Olio, D. and Sträng, E. and Turki, A.T. and Tettero, J.M. and Barbus, M. and Schulze-Rath, R. and Elicegui, J.M. and Matteuzzi, T. and Merlotti, A. and Carota, L. and Sala, C. and Della Porta, M.G. and Giampieri, E. and Hernández-Rivas, J.M. and Bullinger, L. and Castellani, G.
PLoS Computational Biology 20 (2): e1011299. 2 February 2024

Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes.
Noerenberg, D. and Briest, F. and Hennch, C. and Yoshida, K. and Hablesreiter, R. and Takeuchi, Y. and Ueno, H. and Staiger, A.M. and Ziepert, M. and Asmar, F. and Locher, B.N. and Toth, E. and Weber, T. and Amini, R.M. and Klapper, W. and Bouzani, M. and Poeschel, V. and Rosenwald, A. and Held, G. and Campo, E. and Ishaque, N. and Stamatopoulos, K. and Kanellis, G. and Anagnostopoulos, I. and Bullinger, L. and Goldschmidt, N. and Zinzani, P.L. and Bödör, C. and Rosenquist, R. and Vassilakopoulos, T.P. and Ott, G. and Ogawa, S. and Damm, F.
Journal of Clinical Oncology 42 (4): 452-466. 1 February 2024

Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Oerlemans, S. and De Rooij, B.H. and Bennink, C. and Bullinger, L. and Broijl, A. and D'Agostino, M. and Laane, E. and Lupo-Stanghellini, M.T. and Perrot, A. and Wester, R. and Cursaru, V. and Scheurer, H. and Vesseur, J. and Dalal, M. and Sen, R. and Stamm, T. and Ludwig, H. and Sonneveld, P.
Haematologica 1 February 2024 (In Press)

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam, C. and Porter, A.H. and Song, A. and Vroeg In de Wei, G. and Stoll, T. and Straube, J. and Cooper, L. and Cheng, G. and Kahl, V.F.S. and Sobinoff, A.P. and Ling, V.Y. and Jebaraj, B.M.C. and Janardhanan, Y. and Haldar, R. and Bray, L.J. and Bullinger, L. and Heidel, F.H. and Kennedy, G.A. and Hill, M.M. and Pickett, H.A. and Abdel-Wahab, O. and Hartel, G. and Lane, S.W.
Nature Cancer 5 (1): 47-65. January 2024

2023

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.
Klever, M.K. and Sträng, E. and Hetzel, S. and Jungnitsch, J. and Dolnik, A. and Schöpflin, R. and Schrezenmeier, J.F.F. and Schick, F. and Blau, O. and Westermann, J. and Rücker, F.G. and Xia, Z. and Döhner, K. and Schrezenmeier, H. and Spielmann, M. and Meissner, A. and Melo, U.S. and Mundlos, S. and Bullinger, L.
Blood Advances 7 (21): 6520-6531. 14 November 2023

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn, E. and Saadati, M. and Fenaux, P. and Gobbi, M. and Roboz, G.J. and Bullinger, L. and Lutsik, P. and Riedel, A. and Plass, C. and Jahn, N. and Walter, C. and Holzmann, K. and Hao, Y. and Naim, S. and Schreck, N. and Krzykalla, J. and Benner, A. and Keer, H.N. and Azab, M. and Döhner, K. and Döhner, H.
Leukemia 37 (11): 2187-2196. November 2023

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest, F. and Noerenberg, D. and Hennch, C. and Yoshida, K. and Hablesreiter, R. and Nimo, J. and Sasca, D. and Kirchner, M. and Mansouri, L. and Inoue, Y. and Wiegand, L. and Staiger, A.M. and Casadei, B. and Korkolopoulou, P. and Weiner, J. and Lopez-Guillermo, A. and Warth, A. and Schneider, T. and Nagy, Á. and Klapper, W. and Hummel, M. and Kanellis, G. and Anagnostopoulos, I. and Mertins, P. and Bullinger, L. and Rosenquist, R. and Vassilakopoulos, T.P. and Ott, G. and Ogawa, S. and Damm, F.
Leukemia 37 (11): 2237-2249. November 2023

Recent advances in precision medicine for acute myeloid leukemia.
Hernández-Sánchez, A. and Bullinger, L.
Current Opinion in Oncology 35 (6): 581-588. November 2023

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
Schmutz, M. and Zucknick, M. and Schlenk, R.F. and Mertens, D. and Benner, A. and Weichenhan, D. and Mücke, O. and Döhner, K. and Plass, C. and Bullinger, L. and Claus, R.
Clinical Epigenetics 15 (1): 171. 26 October 2023

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
Eifert, T. and Hsu, C.J. and Becker, A.L. and Graessle, S. and Horne, A. and Bemmann, F. and Zhang, Q. and Heuser, M. and Vasioukhin, V. and Scholl, S. and Hochhaus, A. and Siegerist, F. and Endlich, N. and Bullinger, L. and Lane, S.W. and Haas, S. and Schnoeder, T.M and Heidel, F.H.
Leukemia 37 (10): 2027-2035. October 2023

Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients.
Panagiota, V. and Kerschbaum, J.F. and Penack, O. and Stein, C.M. and Arends, C.M. and Koenecke, C. and Strzelecka, P.M. and Kloos, A. and Wiegand, L. and Lasch, A. and Altwasser, R. and Halik, A. and Gabdoulline, R. and Thomson, J. and Weibl, K. and Franke, G.N. and Berger, C. and Hasenkamp, J. and Ayuk, F. and Na, I.K. and Beutel, G. and Keller, U. and Bullinger, L. and Wulf, G.G. and Kröger, N. and Vucinic, V. and Heuser, M. and Damm, F.
HemaSphere 7 (10): e957. October 2023

The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of an inverted 55 base pair ABL1 intron 1b sequence: a detailed molecular analysis.
Burmeister, T. and Bullinger, L. and le Coutre, P.
Acta Haematologica 146 (5): 413-418. October 2023

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski, K. and Perez, A. and Iacoboni, G. and Blumenberg, V. and Bücklein, V.L. and Völkl, S. and Penack, O. and Albanyan, O. and Stock, S. and Müller, F. and Karschnia, P. and Petrera, A. and Reid, K. and Faramand, R. and Davila, M.L. and Modi, K. and Dean, E.A. and Bachmeier, C. and von Bergwelt-Baildon, M. and Locke, F.L. and Bethge, W. and Bullinger, L. and Mackensen, A. and Barba, P. and Jain, M.D. and Subklewe, M.
Science Advances 9 (38): eadg3919. 22 September 2023

Mechanisms of resistance to small molecules in acute myeloid leukemia.
Lang, T.J.L. and Damm, F. and Bullinger, L. and Frick, M.
Cancers 15 (18): 4573. 15 September 2023

Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker, M.S. and Potthoff, S.K. and Lena, A. and Porthun, J. and Hadzibegovic, S. and Evertz, R. and Denecke, C. and Fröhlich, A.K. and Sonntag, F. and Regitz-Zagrosek, V. and Rosen, S.D. and Lyon, A.R. and Lüscher, T.F. and Spertus, J.A. and Anker, S.D. and Karakas, M. and Bullinger, L. and Keller, U. and Landmesser, U. and Butler, J. and von Haehling, S.
European Journal of Heart Failure 25 (9): 1635-1647. September 2023

Hand grip strength in patients with advanced cancer: a prospective study.
Hadzibegovic, S. and Porthun, J. and Lena, A. and Weinlaänder, P. and Lück, L.C. and Potthoff, S.K. and Rösnick, L. and Fröhlich, A.K. and Ramer, L.V. and Sonntag, F. and Wilkenshoff, U. and Ahn, J. and Keller, U. and Bullinger, L. and Mahabadi, A.A. and Totzeck, M. and Rassaf, T. and von Haehling, S. and Coats, A.J.S. and Anker, S.D. and Roeland, E.J. and Landmesser, U. and Anker, M.S.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1682-1694. August 2023

Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use.
Bücklein, V. and Perez, A. and Rejeski, K. and Iacoboni, G. and Jurinovic, V. and Holtick, U. and Penack, O. and Kharboutli, S. and Blumenberg, V. and Ackermann, J. and Frölich, L. and Johnson, G. and Patel, K. and Arciola, B. and Mhaskar, R. and Wood, A. and Schmidt, C. and Albanyan, O. and Gödel, P. and Hoster, E. and Bullinger, L. and Mackensen, A. and Locke, F. and von Bergwelt, M. and Barba, P. and Subklewe, M. and Jain, M.D.
HemaSphere 7 (8): e907. August 2023

Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer.
Anker, M.S. and Lena, A. and Roeland, E.J. and Porthun, J. and Schmitz, S. and Hadzibegovic, S. and Sikorski, P. and Wilkenshoff, U. and Fröhlich, A.K. and Ramer, L.V. and Rose, M. and Eucker, J. and Rassaf, T. and Totzeck, M. and Lehmann, L.H. and von Haehling, S. and Coats, A.J.S. and Friede, T. and Butler, J. and Anker, S.D. and Riess, H. and Landmesser, U. and Bullinger, L. and Keller, U. and Ahn, J.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1670-1681. August 2023

Personalizing precision medicine: Patients with AML perceptions about treatment decisions.
Grauman, A. and Kontro, M. and Haller, K. and Nier, S. and Aakko, S. and Lang, K. and Zingaretti, C. and Meggiolaro, E. and De Padova, S. and Marconi, G. and Martinelli, G. and Heckman, C.A. and Simonetti, G. and Bullinger, L. and Kihlbom, U.
Patient Education and Counseling 115 : 107883. 5 July 2023

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner, H. and Weber, D. and Krzykalla, J. and Fiedler, W. and Kühn, M.W.M. and Schroeder, T. and Mayer, K. and Lübbert, M. and Wattad, M. and Götze, K. and Fransecky, L. and Koller, E. and Wulf, G. and Schleicher, J. and Ringhoffer, M. and Greil, R. and Hertenstein, B. and Krauter, J. and Martens, U.M. and Nachbaur, D. and Samra, M.A. and Machherndl-Spandl, S. and Basara, N. and Leis, C. and Schrade, A. and Kapp-Schwoerer, S. and Cocciardi, S. and Bullinger, L. and Thol, F. and Heuser, M. and Paschka, P. and Gaidzik, V.I. and Saadati, M. and Benner, A. and Schlenk, R.F. and Döhner, K. and Ganser, A.
Lancet Haematology 10 (7): e495-e509. July 2023

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke, M.L. and Neagoie, A. and Blau, I.W. and Wais, V. and Vuong, L. and Gantner, A. and Ahn, J. and Penack, O. and Schnell, J. and Nogai, K.A. and Eberspächer, B. and Saadati, M. and Benner, A. and Bullinger, L. and Döhner, H. and Bunjes, D. and Sala, E.
Frontiers in Immunology 14 : 1174289. 3 May 2023

Clinical and prognostic relevance of cardiac wasting in patients with advanced cancer.
Lena, A. and Wilkenshoff, U. and Hadzibegovic, S. and Porthun, J. and Rösnick, L. and Fröhlich, A.K. and Zeller, T. and Karakas, M. and Keller, U. and Ahn, J. and Bullinger, L. and Riess, H. and Rosen, S.D. and Lyon, A.R. and Lüscher, T.F. and Totzeck, M. and Rassaf, T. and Burkhoff, D. and Mehra, M.R. and Bax, J.J. and Butler, J. and Edelmann, F. and Haverkamp, W. and Anker, S.D. and Packer, M. and Coats, A.J.S. and von Haehling, S. and Landmesser, U. and Anker, M.S.
Journal of the American College of Cardiology 81 (16): 1569-1586. 25 April 2023

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Straube, J. and Eifert, T. and Vu, T. and Janardhanan, Y. and Haldar, R. and von Eyss, B. and Cooper, L. and Bruedigam, C. and Ling, V.Y. and Cooper, E. and Patch, A.M. and Bullinger, L. and Schnoeder, T.M. and Bywater, M. and Heidel, F.H. and Lane, S.W.
Leukemia 37 (4): 741-750. April 2023

Retained functional normal and preleukemic HSCs at diagnosis are associated to good prognosis in DNMT3Amut NPM1mut AMLs.
Donato, E. and Correia, N.C. and Andresen, C. and Karpova, D. and Würth, R. and Klein, C. and Sohn, M. and Przybylla, A. and Zeisberger, P. and Rothfelder, K. and Salih, H.R. and Bonig, H. and Stasik, S. and Röllig, C. and Dolnik, A. and Bullinger, L. and Buchholz, F. and Thiede, C.D. and Hübschmann, D. and Trumpp, A.
Blood Advances 7 (6): 1011-1018. 28 March 2023

Sarcoma patients admitted to the intensive care unit (ICU): predictive relevance of common sepsis and performance parameters.
Striefler, J.K. and Binder, P.T. and Brandes, F. and Rau, D. and Wittenberg, S. and Kaul, D. and Roohani, S. and Jarosch, A. and Schäfer, F.M. and Öllinger, R. and Märdian, S. and Bullinger, L. and Eckardt, K.U. and Kruse, J. and Flörcken, A.
Cancer Management and Research 15 : 321-334. 27 March 2023

Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke.
Arends, C.M. and Liman, T.G. and Strzelecka, P.M. and Kufner, A. and Löwe, P. and Huo, S. and Stein, C.M. and Piper, S.K. and Tilgner, M. and Sperber, P.S. and Dimitriou, S. and Heuschmann, P. and Hablesreiter, R. and Harms, C. and Bullinger, L. and Weber, J.E. and Endres, M. and Damm, F.
Blood 141 (7): 787-799. 16 February 2023

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Zaleska, J. and Kwasnik, P. and Paziewska, M. and Purkot, Jo. and Szabelak, A. and Jurek, M. and Masny, N. and Dziatkiewicz, I. and Pronobis-Szczylik, B. and Piebiak, A. and Szymczyk, A. and Jarosz-Chudzik, K. and Bolkun, L. and Kozlowska, K. and Piszcz, J. and Subocz, E. and Halka, J. and Bator, M. and Kalicinska, E. and Wrobel, T. and Usnarska-Zubkiewicz, L. and Rybka, J. and Deren-Wagemann, I. and Szyca-Smieszniak, M. and Dybko, J. and Hus, I. and Pula, B. and Cichocka, E. and Rymko, M. and Zdunczyk, D. and Ziarkiewicz, M. and Basak, G.W. and Bullinger, L. and Giannopoulos, K.
International Journal of Cancer 15 (4): 705-712. 15 February 2023

Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation.
Obermayer, B. and Keilholz, L. and Conrad, T. and Frentsch, M. and Blau, I.W. and Vuong, L. and Lesch, S. and Movasshagi, K. and Tietze-Stolley, C. and Loyal, L. and Henze, L. and Penack, O. and Stervbo, U. and Babel, N. and Haas, S. and Beule, D. and Bullinger, L. and Wittenbecher, Friedrich and Na, I.K.
Frontiers in Immunology 14 : 1114368. 10 February 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri, L. and Thorvaldsdottir, B. and Sutton, L.A. and Karakatsoulis, G. and Meggendorfer, M. and Parker, H. and Nadeu, F. and Brieghel, C. and Laidou, S. and Moia, R. and Rossi, D. and Catherwood, M. and Kotaskova, J. and Delgado, J. and Rodríguez-Vicente, A.E. and Benito, R. and Rigolin, G.M. and Bonfiglio, S. and Scarfo, L. and Mattsson, M. and Davis, Z. and Gogia, A. and Rani, L. and Baliakas, P. and Foroughi-Asl, H. and Jylhä, C. and Skaftason, A. and Rapado, I. and Miras, F. and Martinez-Lopez, J. and de la Serna, J. and Rivas, J.M.H. and Thornton, P. and Larráyoz, M.J. and Calasanz, M.J. and Fésüs, V. and Mátrai, Z. and Bödör, C. and Smedby, K.E. and Espinet, B. and Puiggros, A. and Gupta, R. and Bullinger, L. and Bosch, F. and Tazón-Vega, B. and Baran-Marszak, F. and Oscier, D. and Nguyen-Khac, F. and Zenz, T. and Terol, M.J. and Cuneo, A. and Hernández-Sánchez, M. and Pospisilova, S. and Mills, K. and Gaidano, G. and Niemann, C.U. and Campo, E. and Strefford, J.C. and Ghia, P. and Stamatopoulos, K. and Rosenquist, R.
Leukemia 37 (2): 339-347. February 2023

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen, A. and Ben Hamza, A. and Welters, C. and Dietze, K. and Bullinger, L. and Rahn, H.P. and Hartmann, S. and Hansmann, M.L. and Hansmann, L.
Cancer Immunology Immunotherapy 72 (2): 515-521. February 2023

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger, C.M. and Janssen, M. and Schäkel, U. and Gall, J. and Leo, A. and Stelmach, P. and Weber, S.F. and Krisam, J. and Baumann, L. and Stermann, J. and Merle, U. and Weigand, M.A. and Nusshag, C. and Bullinger, L. and Schrezenmeier, J.F. and Bornhäuser, M. and Alakel, N. and Witzke, O. and Wolf, T. and Vehreschild, M.J.G.T. and Schmiedel, S. and Addo, M.M. and Herth, F. and Kreuter, M. and Tepasse, P.R. and Hertenstein, B. and Hänel, M. and Morgner, A. and Kiehl, M. and Hopfer, O. and Wattad, M.A. and Schimanski, C.C. and Celik, C. and Pohle, T. and Ruhe, M. and Kern, W.V. and Schmitt, A. and Lorenz, H.M. and Souto-Carneiro, M. and Gaeddert, M. and Halama, N. and Meuer, S. and Kräusslich, H.G. and Müller, B. and Schnitzler, P. and Parthé, S. and Bartenschlager, R. and Gronkowski, M. and Klemmer, J. and Schmitt, M. and Dreger, P. and Kriegsmann, K. and Schlenk, Ri.F. and Müller-Tidow, C.
Nature Cancer 4 (1): 96-107. January 2023

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Weller, J. and Schäfer, N. and Schaub, C. and Tzaridis, T. and Zeyen, T. and Schneider, M. and Potthoff, A.L. and Giordano, F.A. and Steinbach, J.P. and Zeiner, P.S. and Kowalski, T. and Sabel, M. and Hau, P. and Krex, D. and Grauer, O. and Goldbrunner, R. and Schnell, O. and Tabatabai, G. and Ringel, F. and Schmidt-Graf, F. and Brehmer, S. and Tonn, J.C. and Bullinger, L. and Vajkoczy, P. and Glas, M. and Vatter, H. and Herrlinger, U. and Seidel, C.
Journal of Neuro-Oncology 161 (1): 147-153. January 2023

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling, V.Y. and Straube, J. and Godfrey, W. and Haldar, R. and Janardhanan, Y. and Cooper, L. and Bruedigam, C. and Cooper, E. and Tavakoli Shirazi, P. and Jacquelin, S. and Tey, S.K. and Baell, J. and Huang, F. and Jin, J. and Zhao, Y. and Bullinger, L. and Bywater, M.J. and Lane, S.W.
Leukemia 37 (1): 143-153. January 2023

2022

Relapse of NPM1-mutated AML with extramedullary manifestation 17 years after allogeneic hematopoietic stem cell transplantation.
Braune, J. and Rieger, K. and Blau, O. and Keller, U. and Bullinger, L. and Krönke, J.
Case Reports in Hematology 2022 : 3317936. 28 December 2022

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck, F. and Fischer, B. and Witt, M. and Muschhammer, J. and Oelrich, J. and da Costa Avelar, P.H. and Tsoka, S. and Bullinger, L. and Seubert, E. and Smit, D.J. and Bokemeyer, C. and Ackermann, C. and Wellbrock, J. and Haag, F. and Fiedler, W.
Journal for ImmunoTherapy of Cancer 10 (12): e004794. 22 December 2022

Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma.
Welters, C. and Lammoglia Cobo, M.F. and Stein, C.A. and Hsu, M.T. and Ben Hamza, A. and Penter, L. and Chen, X. and Buccitelli, C. and Popp, O. and Mertins, P. and Dietze, K. and Bullinger, L. and Moosmann, A. and Blanc, E. and Beule, D. and Gerbitz, A. and Strobel, J. and Hackstein, H. and Rahn, H.P. and Dornmair, K. and Blankenstein, T. and Hansmann, L.
Cancer Immunology Research 10 (11): 1407-1419. 1 November 2022

Widely applicable, extended flow cytometric stem cell enumeration panel for quality control of advanced cellular products.
Haussmann, K. and Streitz, M. and Takvorian, A. and Grund, J. and Skenderi, Z. and Tietze-Bürger, C. and Movassaghi, K. and Künkele, A. and Blum, A. and Bullinger, L.
Scientific Reports 12 (1): 17995. 26 October 2022

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial.
Denkinger, C.M. and Janssen, M. and Schäkel, U. and Gall, J. and Leo, A. and Stelmach, P. and Weber, S.F. and Krisam, J. and Baumann, L. and Stermann, J. and Merle, U. and Weigand, M.A. and Nusshag, C. and Bullinger, L. and Schrezenmeier, J.F. and Bornhäuser, M. and Alakel, N. and Witzke, O. and Wolf, T. and Vehreschild, M.J.G.T. and Schmiedel, S. and Addo, M.M. and Herth, F. and Kreuter, M. and Tepasse, P.R. and Hertenstein, B. and Hänel, M. and Morgner, A. and Kiehl, M. and Hopfer, O. and Wattad, M.A. and Schimanski, C.C. and Celik, C. and Pohle, T. and Ruhe, M. and Kern, W.V. and Schmitt, A. and Lorenz, H.M. and Souto-Carneiro, M. and Gaeddert, M. and Halama, N. and Meuer, S. and Kräusslich, H.G. and Müller, B. and Schnitzler, P. and Parthé, S. and Bartenschlager, R. and Gronkowski, M. and Klemmer, J. and Schmitt, M. and Dreger, P. and Kriegsmann, K. and Schlenk, R.F. and Müller-Tidow, C.
medRxiv : 2022.10.10.22280850. 13 October 2022

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in hematologY added value framework for hematologic malignancies: a comparative analysis of existing tools.
Cerisoli, F. and Ali, F. and Bereczky, T. and Bolaños, N. and Bullinger, L. and Dhanasiri, S. and Gallagher, J. and Pérez, S.G. and Geissler, J. and Guillevic, Y. and Harrison, K. and Naoum, A. and Portulano, C. and Rodríguez Vicente, A.E. and Schulze-Rath, R. and Gómez, G.Y. and Sanz, G. and Hernández Rivas, J.M.
Value in Health 25 (10): 1760-1767. October 2022

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner, H. and Weber, D. and Krzykalla, J. and Fiedler, W. and Wulf, G.G. and Salih, H.R. and Lübbert, M. and Kühn, M. and Schroeder, T. and Salwender, H. and Götze, K.S. and Westermann, J. and Fransecky, L. and Mayer, K. and Hertenstein, B. and Ringhoffer, M. and Tischler, H.J. and Machherndl-Spandl, S. and Schrade, A. and Paschka, P. and Gaidzik, V.I. and Theis, F. and Thol, F.R. and Heuser, M. and Schlenk, R.F. and Bullinger, L. and Saadati, M. and Benner, A. and Larson, R.A. and Stone, R.M. and Döhner, K. and Ganser, A.
Blood Advances 6 (18): 5345-5355. 27 September 2022

Comorbidities rather than older age define outcome in adult patients with tumors of the Ewing sarcoma family.
Striefler, J.K. and Schmiester, M. and Brandes, F. and Dörr, A. and Pahl, S. and Kaul, D. and Rau, D. and Dobrindt, E.M. and Koulaxouzidis, G. and Bullinger, L. and Märdian, S. and Flörcken, A.
Cancer Medicine 11 (17): 3213-3225. September 2022

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N. and Jahn, E. and Saadati, M. and Bullinger, L. and Larson, R.A. and Ottone, T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Ehninger, G. and Heuser, M. and Ganser, A. and Pallaud, C. and Gathmann, I. and Krzykalla, J. and Benner, A. and Bloomfield, C.D. and Thiede, C. and Stone, R.M. and Döhner, H. and Döhner, K.
Leukemia 36 (9): 2218-2227. September 2022

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K. and Schmalbrock, L.K. and Jung, P. and Bumeder, I. and Kiewe, P. and Hecker, J.S. and Verbeek, M. and Westermann, J. and Bullinger, L. and Keller, U. and Bassermann, F. and Krönke, J. and Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

Precision medicine in myeloid malignancies.
Westermann, J. and Bullinger, L.
Seminars in Cancer Biology 84 : 153-169. September 2022

Concomitant cytotoxic effector differentiation of CD4(+) and CD8(+) T cells in response to EBV-Infected B cells.
Tamura, Y. and Yamane, K. and Kawano, Y. and Bullinger, L. and Wirtz, T. and Weber, T. and Sander, S. and Ohki, S. and Kitajima, Y. and Okada, S. and Rajewsky, K. and Yasuda, T.
Cancers 14 (17): 4118. 25 August 2022

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Zhai, Y. and Singh, P. and Dolnik, A. and Brazda, P. and Atlasy, N. and Del Gaudio, N. and Döhner, K. and Döhner, H. and Minucci, S. and Martens, J. and Altucci, L. and Megchelenbrink, W. and Bullinger, L. and Stunnenberg, H.G.
Molecular Cancer 21 (1): 166. 19 August 2022

The landscape of genetic aberrations in myxofibrosarcoma.
Takeuchi, Y. and Yoshida, K. and Halik, A. and Kunitz, A. and Suzuki, H. and Kakiuchi, N. and Shiozawa, Y. and Yokoyama, A. and Inoue, Y. and Hirano, T. and Yoshizato, T. and Aoki, K. and Fujii, Y. and Nannya, Y. and Makishima, H. and Pfitzner, B.M. and Bullinger, L. and Hirata, M. and Jinnouchi, K. and Shiraishi, Y. and Chiba, K. and Tanaka, H. and Miyano, S. and Okamoto, T. and Haga, H. and Ogawa, S. and Damm, F.
International Journal of Cancer 151 (4): 565-577. 15 August 2022

Unified classification and risk-stratification in Acute Myeloid Leukemia.
Tazi, Y. and Arango-Ossa, J.E. and Zhou, Y. and Bernard, E. and Thomas, I. and Gilkes, A. and Freeman, S. and Pradat, Y. and Johnson, S.J. and Hills, R. and Dillon, R. and Levine, M.F. and Leongamornlert, D. and Butler, A. and Ganser, A. and Bullinger, L. and Döhner, K. and Ottmann, O. and Adams, R. and Döhner, H. and Campbell, P.J. and Burnett, A.K. and Dennis, M. and Russell, N.H. and Devlin, S.M. and Huntly, B.J.P. and Papaemmanuil, E.
Nature Communications 13 (1): 4622. 8 August 2022

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy.
Ihlow, J. and Gross, S. and Busack, L. and Flörcken, A. and Jesse, J. and Schwarz, M. and Neuendorff, N.R. and von Brünneck, A.C. and Anagnostopoulos, I. and Türkmen, S. and Blau, I.W. and Burmeister, T. and Horst, D. and Bullinger, L. and Westermann, J.
Haematologica 107 (8): 1773-1785. August 2022

Application of precision medicine in clinical routine in haematology - challenges and opportunities.
Wästerlid, T. and Cavelier, L. and Haferlach, C. and Konopleva, M. and Fröhling, S. and Östling, P. and Bullinger, L. and Fioretos, T. and Smedby, K.E.
Journal of Internal Medicine 292 (2): 243-261. August 2022

Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls.
Winkelmann, N. and Schwarz, M. and Hildebrandt, B. and Henke, O. and Bullinger, L. and Na, I.K. and Stintzing, S. and le Coutre, P.
eJHaem: The Official Journal of the British Society for Haematology 3 (3): 949-953. August 2022

Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo, M.F. and Welters, C. and Rosenberger, L. and Leisegang, M. and Dietze, K. and Pircher, C. and Penter, L. and Gary, R. and Bullinger, L. and Takvorian, A. and Moosmann, A. and Dornmair, K. and Blankenstein, T. and Kammertöns, T. and Gerbitz, A. and Hansmann, L.
Cytotherapy 24 (8): 818-826. August 2022

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, A.C. and Calvo, I.A. and Cenzano, I. and Olaverri, D. and Cocera, M. and San Martin-Uriz, P. and Romero, J.P. and Vilas-Zornoza, A. and Vera, L. and Gomez-Cebrian, N. and Puchades-Carrasco, L. and Lisi-Vega, L.E. and Apaolaza, I. and Valera, P. and Guruceaga, E. and Granero-Molto, F. and Ripalda-Cemborain, P. and Luck, T.J. and Bullinger, L. and Planes, F.J. and Rifon, J.J. and Méndez-Ferrer, S. and Yusuf, R.Z. and Pardo-Saganta, A. and Prosper, F. and Saez, B.
Leukemia 36 (8): 1969-1979. August 2022

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
Grasedieck, S. and Cabantog, A. and MacPhee, L. and Im, J. and Ruess, C. and Demir, B. and Sperb, N. and Rücker, F.G. and Döhner, K. and Herold, T. and Pollack, J.R. and Bullinger, L. and Rouhi, A. and Kuchenbauer, F.
Haematologica 107 (8): 1758-1772. August 2022

Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity.
Feldkamp, J.D. and Vetter, V.M. and Arends, C.M. and Lang, T.J.L. and Bullinger, L. and Damm, F. and Demuth, I. and Frick, M.
Haematologica 107 (7): 1703-1708. July 2022

Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma.
Schmiester, M. and Maier, R. and Riedel, R. and Durek, P. and Frentsch, M. and Kolling, S. and Mashreghi, M.F. and Jenq, R. and Zhang, L. and Peterson, C.B. and Bullinger, L. and Chang, H.D. and Na, I.K.
Gut Microbes 14 (1): e2081475. 29 May 2022

Paired donor and recipient immunophenotyping in allogeneic hematopoietic stem cell transplantation: a cellular network approach.
Wittenbecher, F. and Lesch, S. and Kolling, S. and Blau, I.W. and Vuong, L. and Borchert, F. and Movasshagi, K. and Tietze-Bürger, C. and Penack, O. and Ahn, J. and Bullinger, L. and Frentsch, M. and Na, I.K.
Frontiers in Immunology 13 : 874499. 23 May 2022

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K. and Perez, A. and Iacoboni, G. and Penack, O. and Bücklein, V. and Jentzsch, L. and Mougiakakos, D. and Johnson, G. and Arciola, B. and Carpio, C. and Blumenberg, V. and Hoster, E. and Bullinger, L. and Locke, F.L. and von Bergwelt-Baildon, M. and Mackensen, A. and Bethge, W. and Barba, P. and Jain, M.D. and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.
Hernández-Malmierca, P. and Vonficht, D. and Schnell, A. and Uckelmann, H.J. and Bollhagen, A. and Mahmoud, M.A.A. and Landua, S.L. and van der Salm, E. and Trautmann, C. and Raffel, S. and Grünschläger, F. and Lutz, R. and Ghosh, M. and Renders, S. and Correia, N. and Donato, E. and Dixon, K.O. and Hirche, C. and Andresen, C. and Robens, Cl. and Werner, P.S. and Boch, T. and Eisel, D. and Osen, W. and Pilz, F. and Przybylla, A. and Klein, C. and Buchholz, F. and Milsom, M.D. and Essers, M.A.G. and Eichmüller, S.B. and Hofmann, W.K. and Nowak, D. and Hübschmann, D. and Hundemer, M. and Thiede, C. and Bullinger, L. and Müller-Tidow, C. and Armstrong, S.A. and Trumpp, A. and Kuchroo, V.K. and Haas, S.
Cell Stem Cell 29 (5): 760-775. 5 May 2022

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer, G. and Bullinger, L. and Garcia-Vidal, C. and Herbrecht, R. and Maertens, J. and Menna, P. and Pagano, L. and Thiebaut-Bertrand, A. and Calandra, T.
Leukemia 36 (5): 1215-1226. May 2022

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla, G. and Radecke, C. and Frentsch, M. and Walther, W. and Stintzing, S. and Riess, H. and Bullinger, L. and Na, I.K.
OncoImmunology 11 (1): 2068109. 25 April 2022

EASIX and severe endothelial complications after CD19-directed CAR-T Cell therapy-a cohort study.
Korell, F. and Penack, O. and Mattie, M. and Schreck, N. and Benner, A. and Krzykalla, J. and Wang, Z. and Schmitt, M. and Bullinger, L. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Frontiers in Immunology 13 : 877477. 8 April 2022

FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Raschzok, N. and Stintzing, S. and Heinemann, V. and Rauch, G. and Ricke, J. and Guckenberger, M. and Kurreck, A. and Alig, A.H.S. and Stahler, A. and Bullinger, L. and Schmelzle, M. and Schöning, W. and Lurje, G. and Krenzien, F. and Haase, O. and Rau, B. and Gebauer, B. and Sauer, I.M. and Pratschke, J. and Modest, D.P.
BMC Cancer 22 (1): 359. 2 April 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus.
Buske, C. and Dreyling, M. and Alvarez-Larrán, A. and Apperley, J. and Arcaini, L. and Besson, C. and Bullinger, L. and Corradini, P. and Della Porta, M.G. and Dimopoulos, M. and D’Sa, S. and Eich, H.T. and Foà, R. and Ghia, P. and Gomes da Silva, M. and Gribben, J. and Hajek, R. and Harrison, C. and Heuser, M. and Kiesewetter, B. and Kiladjian, J.J. and Kröger, N. and Moreau, P. and Passweg, J.R. and Peyvandi, F. and Rea, D. and Ribera, J.M. and Robak, T. and San-Miguel, J.F. and Santini, V. and Sanz, G. and Sonneveld, P. and von Lilienfeld-Toal, M. and Wendtner, C. and Pentheroudakis, G. and Passamonti, F.
ESMO Open 7 (2): 100403. April 2022

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen, F. and Hablesreiter, R. and Hoyer, K. and Hennch, C. and Maluck-Böttcher, A. and Segler, A. and Madadi, A. and Frick, M. and Bullinger, L. and Briest, F. and Damm, F.
Leukemia 36 (4): 1102-1110. April 2022

Refining AML treatment: the role of genetics in response and resistance evaluation to new agents.
Halik, A. and Arends, C.M. and Bullinger, L. and Damm, F. and Frick, M.
Cancers 14 (7): 1689. 26 March 2022

Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome.
Ciraolo, E. and Althoff, S. and Ruß, J. and Rosnev, S. and Butze, M. and Pühl, M. and Frentsch, M. and Bullinger, L. and Na, I.K.
International Journal of Molecular Sciences 23 (6): 3207. 16 March 2022

Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Arends, C.M. and Dimitriou, S. and Stahler, A. and Hablesreiter, R. and Strzelecka, P.M. and Stein, C.M. and Tilgner, M. and Saiki, R. and Ogawa, S. and Bullinger, L. and Modest, D.P. and Stintzing, S. and Heinemann, V. and Damm, F.
Blood 139 (10): 1593-1597. 10 March 2022

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Y.L.D. and Ramberger, E. and Bohl, S.R. and Dolnik, A. and Steinebach, C. and Conrad, T. and Müller, S. and Popp, O. and Kull, M. and Haji, M. and Gütschow, M. and Döhner, H. and Walther, W. and Keller, U. and Bullinger, L. and Mertins, P. and Krönke, J.
Nature Communications 13 (1): 1009. 23 February 2022

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder, T.M. and Schwarzer, A. and Jayavelu, A.K. and Hsu, C.J. and Kirkpatrick, J. and Döhner, K. and Perner, F. and Eifert, T. and Huber, N. and Arreba-Tutusaus, P. and Dolnik, A. and Assi, S.A. and Nafria, M. and Jiang, L. and Dai, Y.T. and Chen, Z. and Chen, S.J. and Kellaway, S.G. and Ptasinska, A. and Ng, E.S. and Stanley, E.G. and Elefanty, A.G. and Buschbeck, M. and Bierhoff, H. and Brodt, S. and Matziolis, G. and Fischer, K.D. and Hochhaus, A. and Chen, C.W. and Heidenreich, O. and Mann, M. and Lane, S.W. and Bullinger, L. and Ori, A. and von Eyss, B. and Bonifer, C. and Heidel, F.
Blood 139 (7): 1080-1097. 17 February 2022

Acute left ventricular insufficiency in a Burkitt Lymphoma patient with myocardial involvement and extensive local tumor cell lysis: a case report.
Schmiester, M. and Tranter, E. and Lorusso, A. and Blaschke, F. and Geisel, D. and Bullinger, L. and Damm, F. and Na, I.K.
BMC Cardiovascular Disorders 22 (1): 31. 4 February 2022

CEBPA mutations in AML: site matters.
Bullinger, L.
Blood 139 (1): 6-7. 6 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S. and Bittner, A. and Frick, M. and Kase, J. and Hoffmann, J. and Trenker, C. and Keller, U. and Bogner, C. and Hüttmann, A. and Dürig, J. and Janz, M. and Mathas, S. and Marks, R. and Krohn, U. and Na, I.K. and Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker, F.G. and Du, L. and Luck, T.J. and Benner, A. and Krzykalla, J. and Gathmann, I. and Voso, M.T. and Amadori, S. and Prior, T.W. and Brandwein, J.M. and Appelbaum, F.R. and Medeiros, B.C. and Tallman, M.S. and Savoie, L. and Sierra, J. and Pallaud, C. and Sanz, M.A. and Jansen, J.H. and Niederwieser, D. and Fischer, T. and Ehninger, G. and Heuser, M. and Ganser, A. and Bullinger, L. and Larson, R.A. and Bloomfield, C.D. and Stone, R.M. and Döhner, H. and Thiede, C. and Döhner, K.
Leukemia 36 (1): 90-99. January 2022

2021

Survey of long-term experiences of sperm cryopreservation in oncological and non-oncological patients: usage and reproductive outcomes of a large monocentric cohort.
Lackamp, N. and Wilkemeyer, I. and Jelas, I. and Keller, U. and Bullinger, L. and Stintzing, S. and le Coutre, P.
Frontiers in Oncology 11 : 772809. 5 November 2021

Netboost: boosting-supported network analysis improves high-dimensional omics prediction in acute myeloid leukemia and Huntington's disease.
Schlosser, P. and Knaus, J. and Schmutz, M. and Döhner, K. and Plass, C. and Bullinger, L. and Claus, R. and Binder, H. and Lübbert, M. and Schumacher, M.
IEEE/ACM Transactions on Computational Biology and Bioinformatics 18 (6): 2635-2648. 1 November 2021

Survivin’ acute myeloid leukaemia - a personalised target for inv(16) patients.
Greiner, J. and Brown, E. and Bullinger, L. and Hills, R.K. and Morris, V. and Döhner, H. and Mills, K.I. and Guinn, B.A.
International Journal of Molecular Sciences 22 (19): 10482. 1 October 2021

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Bloehdorn, J. and Braun, A. and Taylor-Weiner, A. and Jebaraj, B.M.C. and Robrecht, S. and Krzykalla, J. and Pan, H. and Giza, A. and Akylzhanova, G. and Holzmann, K. and Scheffold, A. and Johnston, H.E. and Yeh, R.F. and Klymenko, T. and Tausch, E. and Eichhorst, B. and Bullinger, L. and Fischer, K. and Weisser, M. and Robak, T. and Schneider, C. and Gribben, J. and Dahal, L.N. and Carter, M.J. and Elemento, O. and Landau, D.A. and Neuberg, D.S. and Cragg, M.S. and Benner, A. and Hallek, M. and Wu, C.J. and Döhner, H. and Stilgenbauer, S. and Mertens, D.
Nature Communications 12 (1): 5395. 13 September 2021

58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien [58/f with increasing psychomotor retardation and headache].
Onken, J.S. and Bullinger, L.
Onkologe 27 : 79-84. September 2021

CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation.
Heck, C. and Steiner, S. and Kaebisch, E.M. and Frentsch, M. and Wittenbecher, F. and Scheibenbogen, C. and Hanitsch, L.G. and Nogai, A. and le Coutre, P. and Bullinger, L. and Blau, I.W. and Na, I.K.
Frontiers in Immunology 12 : 736137. September 2021

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport, F. and Neelamraju, Y. and Baslan, T. and Hassane, D. and Gruszczynska, A. and de Massy, M.R. and Farnoud, N. and Haddox, S. and Lee, T. and Medina-Martinez, J. and Sheridan, C. and Thurmond, A. and Becker, M. and Bekiranov, S. and Carroll, M. and Moses Murdock, H. and Valk, P.J.M. and Bullinger, L. and D’Andrea, R. and Lowe, S.W. and Neuberg, D. and Levine, R.L. and Melnick, A. and Garrett-Bakelman, F.E.
Leukemia 35 (9): 2688-2692. September 2021

The EHA Research Roadmap: Malignant Myeloid Diseases.
Döhner, H. and Malcovati, L. and Ossenkoppele, G.J. and Hochhaus, A. and Maria Vannucchi, A. and Bullinger, L. and Cervantes, F. and Craddock, C. and de Witte, T. and Döhner, K. and Dombret, H. and Fenaux, P. and Geissler, J. and Germing, U. and Guilhot, F. and Harrison, C. and Hellström-Lindberg, E. and Passamonti, F. and Sierra, J. and Skoda, R. and Wierzbowska, A.
HemaSphere 5 (9): e635. September 2021

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab.
Dimai, S. and Semmler, L. and Prabhu, A. and Stachelscheid, H. and Huettemeister, J. and Klaucke, S.C. and Lacour, P. and Blaschke, F. and Kruse, J. and Parwani, A. and Boldt, L.H. and Bullinger, L. and Pieske, B.M. and Heinzel, F.R. and Hohendanner, F.
PLoS ONE 16 (8): e0255976. 19 August 2021

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch, M.E. and Kast, R.E. and Karpel-Massler, G. and Mayer, B. and Zolk, O. and Schmitz, B. and Scheuerle, A. and Maier, L. and Bullinger, L. and Mayer-Steinacker, R. and Schmidt, C. and Zeiler, K. and Elshaer, Z. and Panther, P. and Schmelzle, B. and Hallmen, A. and Dwucet, A. and Siegelin, M.D. and Westhoff, M.A. and Beckers, K. and Bouche, G. and Heiland, T.
Neuro-Oncology Advances 3 (1): vdab075. 7 August 2021

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Bittner, A. and Radke, J. and Eurich, D. and Wiener, E. and Denker, S. and Anagnostopoulos, I. and Na, I.K. and Heppner, F.L. and Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 62 (8): 2026-2029. August 2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N. and Duell, J. and Fitzgerald, D. and Kerkhoff, A. and Noerenberg, D. and Kaebisch, E. and Acker, F. and Fuhrmann, S. and Leng, C. and Welslau, M. and Chemnitz, J. and Middeke, J.M. and Weber, T. and Holtick, U. and Trappe, R. and Pfannes, R. and Liersch, R. and Spoer, C. and Fuxius, S. and Gebauer, N. and Caillé, L. and Geer, T. and Koenecke, C. and Keller, U. and Claus, R. and Mougiakakos, D. and Mayer, S. and Huettmann, A. and Pott, C. and Trummer, A. and Wulf, G. and Brunnberg, U. and Bullinger, L. and Hess, G. and Mueller-Tidow, C. and Glass, B. and Lenz, G. and Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

Early bilirubinemia after allogeneic stem cell transplantation - an endothelial complication.
Dai, H. and Penack, O. and Radujkovic, A. and Schult, D. and Majer-Lauterbach, J. and Blau, I.W. and Bullinger, L. and Jiang, S. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Bone Marrow Transplantation 56 (7): 1573-1583. July 2021

Genome sequencing in myeloid cancers.
Dolnik, A. and Schrezenmeier, J. and Bullinger, L.
New England Journal of Medicine 384 (25): e106. 24 June 2021

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S. and Heimann, A. and Obermayer, B. and Ciraolo, E. and Althoff, S. and Ruß, J. and Grunert, C. and Busse, A. and Bullinger, L. and Pezzutto, A. and Blankenstein, T. and Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock, L.K. and Dolnik, A. and Cocciardi, S. and Sträng, E. and Theis, F. and Jahn, N. and Panina, E. and Blätte, T.J. and Herzig, J.K. and Skambraks, S. and Rücker, F.G. and Gaidzik, V.I. and Paschka, P. and Fiedler, W. and Salih, H.R. and Wulf, G.G. and Schroeder, T. and Lübbert, M. and Schlenk, R.F. and Thol, F. and Heuser, M. and Larson, R.A. and Ganser, A. and Stunnenberg, H.G. and Minucci, S. and Stone, R.M. and Bloomfield, C.D. and Döhner, H. and Döhner, K. and Bullinger, L.
Blood 137 (22): 3093-3104. 3 June 2021

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl, S.R. and Schmalbrock, L.K. and Bauhuf, I. and Meyer, T. and Dolnik, A. and Szyska, M. and Blätte, T.J. and Knödler, S. and Röhner, L. and Miller, D. and Kull, M. and Langer, C. and Döhner, H. and Letai, A. and Damm, F. and Heckl, D. and Bullinger, L. and Krönke, J.
Blood Advances 5 (9): 2391-2402. 11 May 2021

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser, M. and Heida, B. and Büttner, K. and Wienecke, C.P. and Teich, K. and Funke, C. and Brandes, M. and Klement, P. and Liebich, A. and Wichmann, M. and Neziri, B. and Chaturvedi, A. and Kloos, A. and Mintzas, K. and Gaidzik, V.I. and Paschka, P. and Bullinger, L. and Fiedler, W. and Heim, A. and Puppe, W. and Krauter, J. and Döhner, K. and Döhner, H. and Ganser, A. and Stadler, M. and Hambach, L. and Gabdoulline, R. and Thol, F.
Blood Advances 5 (9): 2294-2304. 11 May 2021

Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades.
Ihlow, J. and Gross, S. and Neuendorff, N.R. and Busack, L. and Herneth, A. and Singh, A. and Schwarz, M. and Flörcken, A. and Anagnostopoulos, I. and Türkmen, S. and Burmeister, T. and Blau, I.W. and Bullinger, L. and Westermann, J.
Journal of Geriatric Oncology 12 (4): 540-549. May 2021

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.
Giacopelli, B. and Wang, M. and Cleary, A. and Wu, Y.Z. and Schultz, A.R. and Schmutz, M. and Blachly, J.S. and Eisfeld, A.K. and Mundy-Bosse, B. and Vosberg, S. and Greif, P.A. and Claus, R. and Bullinger, L. and Garzon, R. and Coombes, K.R. and Bloomfield, C.D. and Druker, B.J. and Tyner, J.W. and Byrd, J.C. and Oakes, C.C.
Genome Research 31 (5): 747-761. May 2021

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial.
Hoyer, K. and Hablesreiter, R. and Inoue, Y. and Yoshida, K. and Briest, F. and Christen, F. and Kakiuchi, N. and Yoshizato, T. and Shiozawa, Y. and Shiraishi, Y. and Striefler, J.K. and Bischoff, S. and Lohneis, P. and Putter, H. and Blau, O. and Keilholz, U. and Bullinger, L. and Pelzer, U. and Hummel, M. and Riess, H. and Ogawa, S. and Sinn, M. and Damm, F.
EBioMedicine 66 : 103327. April 2021

Deregulated expression of circular RNAs in acute myeloid leukemia.
Lux, S. and Blätte, T.J. and Gillissen, B. and Richter, A. and Cocciardi, S. and Skambraks, S. and Schwarz, K. and Schrezenmeier, H. and Döhner, H. and Döhner, K. and Dolnik, A. and Bullinger, L.
Blood Advances 5 (5): 1490-1503. 9 March 2021

NEMHESYS - European perspective on the implementation of next-generation sequencing into clinical diagnostics.
Serramito-Gómez, I. and Clarke, K.M. and Rodríguez-Vicente, A.E. and McGimpsey, J.E. and Abáigar, M. and Díez, C.B. and Benito, R. and Bullinger, L. and Mills, K.I. and Hernández Rivas, J.M.
HemaSphere 5 (3): e541. March 2021

B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased.
Ihlow, J. and Michaelis, E. and Greuel, S. and Heynol, V. and Lehmann, A. and Radbruch, H. and Meinhardt, J. and Miller, F. and Herbst, H. and Corman, V.M. and Westermann, J. and Bullinger, L. and Horst, D. and von Brünneck, A.C. and Elezkurtaj, S.
International Journal of Infectious Diseases 103 : 628-635. February 2021

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.
Brandes, F. and Striefler, J.K. and Dörr, A. and Schmiester, M. and Märdian, S. and Koulaxouzidis, G. and Kaul, D. and Behzadi, A. and Thuss-Patience, P. and Ahn, J. and Pelzer, U. and Bullinger, L. and Flörcken, A.
BMC Palliative Care 20 (1): 16. 14 January 2021

Gene expression profiling predicts sensitivity of chronic lymphocytic leukemia cells to dasatinib.
Blätte, T.J. and Machnicki, M.M. and Glodkowska-Mrowka, E. and Dolnik, A. and Karp, M. and Karczmarczyk, A. and Giannopoulos, K. and Bullinger, L. and Stoklosa, T.
HemaSphere 5 (1): e514. January 2021

TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester, M. and Dolnik, A. and Kornak, U. and Pfitzner, B. and Hummel, M. and Treue, D. and Hartmann, A. and Agaimy, A. and Weyerer, V. and Lekaj, A. and Brakemeier, S. and Peters, R. and Öllinger, R. and Märdian, S. and Bullinger, L. and Striefler, J.K. and Flörcken, A.
Journal of Pathology Clinical Research 7 (1): 3-9. January 2021

Genomic landscape and clonal evolution of AML.
Noerenberg, D. and Damm, F. and Bullinger, L.
In: Acute Myeloid Leukemia. Hematologic Malignancies . Springer, Cham, 103-118. ISBN 978-3-030-72675-1 2021

2020

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer, S. and Weber, D. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Krönke, J. and Theis, F. and Rücker, F.G. and Teleanu, M.V. and Panina, E. and Jahn, N. and Herzig, J. and Kubanek, L. and Schrade, A. and Göhring, G. and Fiedler, W. and Kindler, T and Schroeder, T. and Mayer, K.T. and Lübbert, M. and Wattad, M. and Götze, K.S. and Horst, H.A. and Koller, E. and Wulf, G. and Schleicher, J. and Bentz, M. and Krauter, J. and Bullinger, L. and Krzykalla, J. and Benner, A. and Schlenk, R.F. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H and Döhner, K.
Blood 136 (26): 3041-3050. 24 December 2020

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn, N. and Terzer, T. and Sträng, E. and Dolnik, A. and Cocciardi, S. and Panina, E. and Corbacioglu, A. and Herzig, J. and Weber, D. and Schrade, A. and Götze, K. and Schröder, T. and Lübbert, M. and Wellnitz, D. and Koller, E. and Schlenk, R.F. and Gaidzik, V.I. and Paschka, P. and Rücker, F.G. and Heuser, M. and Thol, F. and Ganser, A. and Benner, A. and Döhner, H. and Bullinger, L. and Döhner, K.
Blood Advances 4 (24): 6342-6352. 22 December 2020

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Jayavelu, A.K. and Schnöder, T.M. and Perner, F. and Herzog, C. and Meiler, A. and Krishnamoorthy, G. and Huber, N. and Mohr, J. and Edelmann-Stephan, B. and Austin, R. and Brandt, S. and Palandri, F. and Schröder, N. and Isermann, B. and Edlich, F. and Sinha, A.U. and Ungelenk, M. and Hübner, C.A. and Zeiser, R. and Rahmig, S. and Waskow, C. and Coldham, I. and Ernst, T. and Hochhaus, A. and Jilg, S. and Jost, P.J. and Mullally, A. and Bullinger, L. and Mertens, P.R. and Lane, S.W. and Mann, M. and Heidel, F.H.
Nature 588 (7836): 157-163. 3 December 2020

A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial.
Janssen, M. and Schäkel, U. and Djuka Fokou, C. and Krisam, J. and Stermann, J. and Kriegsmann, K. and Haberbosch, I. and Novotny, J.P. and Weber, S. and Vehreschild, M. and Bornhäuser, M. and Bullinger, L. and Schmitt, M. and Liebregts, T. and Dreger, P. and Lorenz, H.M. and Plaszczyca, A. and Bartenschlager, R. and Müller, B. and Kräusslich, H.G. and Halama, N. and Jäger, D. and Schlenk, R.F. and Leo, A. and Meuer, S. and Weigand, M.A. and Motsch, J. and Merle, U. and Denkinger, C.M. and Müller-Tidow, C.
Trials 21 (1): 828. 6 October 2020

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch, E. and Beck, P. and Schlenk, R.F. and Jebaraj, B.M.C. and Dolnik, A. and Yosifov, D.Y. and Hillmen, P. and Offner, F. and Janssens, A. and Babu, K.G. and Grosicki, S. and Mayer, J. and Panagiotidis, P. and McKeown, A. and Gupta, I.V. and Skorupa, A. and Pallaud, C. and Bullinger, L. and Mertens, D. and Döhner, H. and Stilgenbauer, S.
Haematologica 105 (10): 2440-2447. October 2020

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells.
Raffel, S. and Klimmeck, D. and Falcone, M. and Demir, A. and Pouya, A. and Zeisberger, P. and Lutz, C. and Tinelli, M. and Bischel, O. and Bullinger, L. and Thiede, C. and Flörcken, A. and Westermann, J. and Ehninger, G. and Ho, A.D. and Müller-Tidow, C. and Gu, Z. and Herrmann, C. and Krijgsveld, J. and Trumpp, A. and Hansson, J.
Blood 136 (13): 1507-1519. 24 September 2020

Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Yusuf, R.Z. and Saez, B. and Sharda, A. and van Gastel, N. and Yu, V.W.C. and Baryawno, N. and Scadden, E.W. and Acharya, S. and Chattophadhyay, S. and Huang, C. and Viswanathan, V. and S'aulis, D. and Cobert, J. and Sykes, D.B. and Keibler, M.A. and Das, S. and Hutchinson, J.N. and Churchill, M. and Mukherjee, S. and Lee, D. and Mercier, F. and Doench, J. and Bullinger, L. and Logan, D.J. and Schreiber, S. and Stephanopoulos, G. and Rizzo, W.B. and Scadden, D.T.
Blood 136 (11): 1303-1316. 10 September 2020

Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.
In't Hout, F.E.M. and Gerritsen, M. and Bullinger, L. and Van der Reijden, B.A. and Huls, G. and Vellenga, E. and Jansen, J.H.
Haematologica 105 (9): e454-457. 1 September 2020

The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia.
Grasedieck, S. and Ruess, C. and Krowiorz, K. and Lux, S. and Pochert, N. and Schwarzer, A. and Klusmann, J.H. and Jongen-Lavrencic, M. and Herold, T. and Bullinger, L. and Pollack, J.R. and Rouhi, A. and Kuchenbauer, F.
Haematologica 105 (9): e448-e453. September 2020

Endothelial damage and dysfunction in acute graft-versus-host disease.
Cordes, S. and Mokhtari, Z. and Bartosova, M. and Mertlitz, S. and Riesner, K. and Shi, Y. and Mengwasser, J. and Kalupa, M. and McGeary, A. and Schleifenbaum, J. and Schrezenmeier, J. and Bullinger, L. and Diaz-Ricart, M. and Palomo, M. and Carrreras, E. and Beutel, G. and Schmitt, C.P. and Beilhack, A. and Penack, O.
Haematologica 106 (8): 2147-2160. 1 August 2020

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber, C. and Correia, N. and Trumpp, A. and Rieger, M.A. and Dolnik, A. and Bullinger, L. and Roeder, I. and Seifert, M.
Scientific Reports 10 (1): 12761. 29 July 2020

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker, H. and Pfeifer, D. and Ihorst, G. and Pantic, M. and Wehrle, J. and Rüter, B.H. and Bullinger, L. and Hackanson, B. and Germing, U. and Kuendgen, A. and Platzbecker, U. and Döhner, K. and Ganser, A. and Hagemeijer, A. and Wijermans, P.W. and Döhner, H. and Duyster, J. and Lübbert, M.
Annals of Hematology 99 (7): 1551-1560. July 2020

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch, E. and Schneider, C. and Robrecht, S. and Zhang, C. and Dolnik, A. and Bloehdorn, J. and Bahlo, J. and Al-Sawaf, O. and Ritgen, M. and Fink, A.M. and Eichhorst, B. and Kreuzer, K.A. and Tandon, M. and Humphrey, K. and Jiang, Y. and Schary, W. and Bullinger, L. and Mertens, D. and Lurà, M.P. and Kneba, M. and Döhner, H. and Fischer, K. and Hallek, M. and Stilgenbauer, S.
Blood 135 (26): 2402-2412. 25 June 2020

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.
Lang, K.M. and Harrison, K.L. and Williamson, P.R. and Huntly, B.J.P. and Ossenkoppele, G. and Geissler, J. and Bereczky, T. and Hernández-Rivas, J.M. and Chevrou-Séverac, H. and Goodbody, R. and Schulze-Rath, R. and Bullinger, L.
Trials 21 (1): 437. 27 May 2020

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.
Edelmann, J. and Holzmann, K. and Tausch, E. and Saunderson, E.A. and Jebaraj, B.M.C. and Steinbrecher, D. and Dolnik, A. and Blätte, T.J. and Landau, D.A. and Saub, J. and Estenfelder, S. and Ibach, S. and Cymbalista, F. and Leblond, V. and Delmer, A. and Bahlo, J. and Robrecht, S. and Fischer, K. and Goede, V. and Bullinger, L. and Wu, C.J. and Mertens, D. and Ficz, G. and Gribben, J.G. and Hallek, M. and Döhner, H. and Stilgenbauer, S.
Haematologica 105 (5): 1379-1390. May 2020

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner, J. and Götz, M. and Hofmann, S. and Schrezenmeier, H. and Wiesneth, M. and Bullinger, L. and Döhner, H. and Schneider, V.
Cancer Immunology Immunotherapy 69 (4): 629-640. April 2020

Functional classification of TP53 mutations in acute myeloid leukemia.
Dutta, S. and Pregartner, G. and Rücker, F.G. and Heitzer, E. and Zebisch, A. and Bullinger, L. and Berghold, A. and Döhner, K. and Sill, H.
Cancers 12 (3): 637. 10 March 2020

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
Agrawal, M. and Schwarz, P. and Giaimo, B.D. and Bedzhov, I. and Corbacioglu, A. and Weber, D. and Gaidzik, V.I. and Jahn, N. and Rücker, F.G. and Schroeder, T. and Kindler, T. and Wattad, M. and Götze, K. and Lübbert, M. and Salwender, H. and Ringhoffer, M. and Lange, E. and Koller, E. and Thol, F. and Heuser, M. and Ganser, A. and Bullinger, L. and Paschka, P. and Döhner, H. and Geiger, H. and Borggrefe, T. and Döhner, K. and Oswald, F.
Leukemia 34 (2): 630-634. February 2020

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
Meyer, T. and Jahn, N. and Lindner, S. and Röhner, L. and Dolnik, A. and Weber, D. and Scheffold, A. and Köpff, S. and Paschka, P. and Gaidzik, V.I. and Heckl, D. and Wiese, S. and Ebert, B.L. and Döhner, H. and Bullinger, L. and Döhner, K. and Krönke, J.
Leukemia 34 (2): 404-415. February 2020

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang, S. and Penack, O. and Terzer, T. and Schult, D. and Majer-Lauterbach, J. and Radujkovic, A. and Blau, I.W. and Bullinger, L. and Müller-Tidow, C. and Dreger, P. and Luft, T.
Haematologica 106 (2): 446-453. February 2020

Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.
Uckelmann, H.J. and Kim, S.M. and Wong, E.M. and Hatton, C. and Giovinazzo, H. and Gadrey, J.Y. and Krivtsov, A.V. and Rücker, F.G. and Döhner, K. and McGeehan, G.M. and Levine, R.L. and Bullinger, L. and Vassiliou, G.S. and Armstrong, S.A.
Science 367 (6477): 586-590. 31 January 2020

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler, J.K. and Brandes, F. and Baur, A. and Pfitzner, B.M. and Kaul, D. and Rau, D. and Dörr, A. and Schmiester, M. and Koulaxouzidis, G. and Bullinger, L. and Märdian, S. and Flörcken, A.
BMC Cancer 20 (1): 68. 29 January 2020

Single-cell analysis based dissection of clonality in myelofibrosis.
Mylonas, E. and Yoshida, K. and Frick, M. and Hoyer, K. and Christen, F. and Kaeda, J. and Obenaus, M. and Noerenberg, D. and Hennch, C. and Chan, W. and Ochi, Y. and Shiraishi, Y. and Shiozawa, Y. and Zenz, T. and Oakes, C.C. and Sawitzki, B. and Schwarz, M. and Bullinger, L. and le Coutre, P. and Rose-Zerilli, M.J.J. and Ogawa, S. and Damm, F.
Nature Communications 11 (1): 73. 7 January 2020

2019

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Rücker, F.G. and Agrawal, M. and Corbacioglu, A. and Weber, D. and Kapp-Schwoerer, S. and Gaidzik, V.I. and Jahn, N. and Schroeder, T. and Wattad, M. and Lübbert, M. and Koller, E. and Kindler, T. and Götze, K. and Ringhoffer, M. and Westermann, J. and Fiedler, W. and Horst, H.A. and Greil, R. and Schroers, R. and Mayer, K. and Heinicke, T. and Krauter, J. and Schlenk, R.F. and Thol, F. and Heuser, M. and Ganser, A. and Bullinger, L. and Paschka, P. and Döhner, H. and Döhner, K.
Blood 134 (19): 1608-1618. 7 November 2019

Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.
Doescher, J. and Weissinger, S.E. and Schönsteiner, S.S. and Lisson, C. and Bullinger, L. and Barth, T.F. and Leithäuser, F. and Mueller-Richter, U. and Laban, S. and Hoffmann, T.K. and Möller, P. and Lennerz, J.K. and Schuler, P.J.
Immunotherapy 11 (14): 1193-1203. October 2019

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller, J. and Tzaridis, T. and Mack, F. and Steinbach, J.P. and Schlegel, U. and Hau, P. and Krex, D. and Grauer, O. and Goldbrunner, R. and Bähr, O. and Uhl, M. and Seidel, C. and Tabatabai, G. and Brehmer, S. and Bullinger, L. and Galldiks, N. and Schaub, C. and Kebir, S. and Stummer, W. and Simon, M. and Fimmers, R. and Coch, C. and Glas, M. and Herrlinger, U. and Schäfer, N.
Lancet Oncology 20 (10): 1444-1453. October 2019

getITD for FLT3-ITD-based MRD monitoring in AML.
Blätte, T.J. and Schmalbrock, L.K. and Skambraks, S. and Lux, S. and Cocciardi, S. and Dolnik, A. and Döhner, H. and Döhner, K. and Bullinger, L.
Leukemia 33 (10): 2535-2539. October 2019

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
Ettrich, T.J. and Schwerdel, D. and Dolnik, A. and Beuter, F. and Blätte, T.J. and Schmidt, S.A. and Stanescu-Siegmund, N. and Steinacker, J. and Marienfeld, R. and Kleger, A. and Bullinger, L. and Seufferlein, T. and Berger, A.W.
Scientific Reports 9 (1): 13261. 13 September 2019

Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
Tausch, E. and Close, W. and Dolnik, A. and Bloehdorn, J. and Chyla, B. and Bullinger, L. and Döhner, H. and Mertens, D. and Stilgenbauer, S.
Haematologica 104 (9): e434-e437. September 2019

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold, A. and Jebaraj, B.M.C. and Tausch, E. and Bloehdorn, J. and Ghia, P. and Yahiaoui, A. and Dolnik, A. and Blätte, T.J. and Bullinger, L. and Dheenadayalan, R.P. and Li, L. and Schneider, C. and Chen, S.S. and Chiorazzi, N. and Dietrich, S. and Seiffert, M. and Tannheimer, S. and Döhner, H. and Mertens, D. and Stilgenbauer, S.
Blood 134 (6): 534-547. 8 August 2019

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen, J.S. and Laursen, L.G. and Schuster, M.B. and Pundhir, S. and Schoof, E. and Ge, Y. and d'Altri, T. and Vitting-Seerup, K. and Rapin, N. and Gentil, C. and Jendholm, J. and Theilgaard-Mönch, K. and Reckzeh, K. and Bullinger, L. and Döhner, K. and Hokland, P. and Fitzgibbon, J. and Porse, B.T.
Science Advances 5 (7): eaaw4304. July 2019

NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
Sasca, D. and Szybinski, J. and Schüler, A. and Shah, V. and Heidelberger, J. and Haehnel, P.S. and Dolnik, A. and Kriege, O. and Fehr, E.M. and Gebhardt, W.H. and Reid, G. and Scholl, C. and Theobald, M. and Bullinger, L. and Beli, P. and Kindler, T.
Blood 133 (21): 2305-2319. 23 May 2019

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Cocciardi, S. and Dolnik, A. and Kapp-Schwoerer, S. and Rücker, F.G. and Lux, S. and Blätte, T.J. and Skambraks, S. and Krönke, J. and Heidel, F.H. and Schnöder, T.M. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Teleanu, V. and Göhring, G. and Thol, F. and Heuser, M. and Ganser, A. and Weber, D. and Sträng, E. and Kestler, H.A. and Döhner, H. and Bullinger, L. and Döhner, K.
Nature Communications 10 (1): 2031. 2 May 2019

Retroperitoneal hematoma after bone marrow biopsy: the first cut should not be the deepest.
Wojciechowski, A. and Duckert, M. and Hartmann, J. and Bullinger, L. and Matzdorff, A.
Oncology Research and Treatment 42 (5): 283-288. May 2019

New targeted agents in acute myeloid leukemia: new hope on the rise.
Bohl, S.R. and Bullinger, L. and Rücker, F.G.
International Journal of Molecular Sciences 20 (8) 23 April 2019

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Jutzi, J.S. and Basu, T. and Pellmann, M. and Kaiser, S. and Steinemann, D. and Sanders, M.A. and Hinai, A.S.A. and Zeilemaker, A. and Bojtine Kovacs, S. and Koellerer, C. and Ostendorp, J. and Aumann, K. and Wang, W. and Raffoux, E. and Cassinat, B. and Bullinger, L. and Schlegelberger, B. and Valk, P.J.M. and Pahl, H.L.
Blood 133 (16): 1766-1777. 18 April 2019

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer, F. and Giotopoulos, G. and Meduri, E. and Yun, H. and Mazan, M. and Sasca, D. and Gallipoli, P. and Marando, L. and Gozdecka, M. and Asby, R. and Sheppard, O. and Dudek, M. and Bullinger, L. and Döhner, H. and Dillon, R. and Freeman, S. and Ottmann, O. and Burnett, A. and Russell, N. and Papaemmanuil, E. and Hills, R. and Campbell, P. and Vassiliou, G.S.. and Huntly, B.J.P.
Journal of Experimental Medicine 216 (4): 966-981. 1 April 2019

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Christen, F. and Hoyer, K. and Yoshida, K. and Hou, H.A. and Waldhueter, N. and Heuser, M. and Hills, R.K. and Chan, W. and Hablesreiter, R. and Blau, O. and Ochi, Y. and Klement, P. and Chou, W.C. and Blau, I.W. and Tang, J.L. and Zemojtel, T. and Shiraishi, Y. and Shiozawa, Y. and Thol, F. and Ganser, A. and Löwenberg, B. and Linch, D.C. and Bullinger, L. and Valk, P.J.M. and Tien, H.F. and Gale, R.E. and Ogawa, S. and Damm, F.
Blood 133 (10): 1140-1151. 7 March 2019

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Simonetti, G. and Padella, A. and do Valle, I.F. and Fontana, M.C. and Fonzi, E. and Bruno, S. and Baldazzi, C. and Guadagnuolo, V. and Manfrini, M. and Ferrari, A. and Paolini, S. and Papayannidis, C. and Marconi, G. and Franchini, E. and Zuffa, E. and Laginestra, M.A. and Zanotti, F. and Astolfi, A. and Iacobucci, I. and Bernardi, S. and Sazzini, M. and Ficarra, E. and Hernandez, J.M. and Vandenberghe, P. and Cools, J. and Bullinger, L. and Ottaviani, E. and Testoni, N. and Cavo, M. and Haferlach, T. and Castellani, G. and Remondini, D. and Martinelli, G.
Cancer 125 (5): 712-725. 1 March 2019

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger, U. and Tzaridis, T. and Mack, F. and Steinbach, J.P. and Schlegel, U. and Sabel, M. and Hau, P. and Kortmann, R.D. and Krex, D. and Grauer, O. and Goldbrunner, R. and Schnell, O. and Bähr, O. and Uhl, M. and Seidel, C. and Tabatabai, G. and Kowalski, T. and Ringel, F. and Schmidt-Graf, F. and Suchorska, B. and Brehmer, S. and Weyerbrock, A. and Renovanz, M. and Bullinger, L. and Galldiks, N. and Vajkoczy, P. and Misch, M. and Vatter, H. and Stuplich, M. and Schäfer, N. and Kebir, S. and Weller, J. and Schaub, C. and Stummer, W. and Tonn, J.C. and Simon, M. and Keil, V.C. and Nelles, M. and Urbach, H. and Coenen, M. and Wick, W. and Weller, M. and Fimmers, R. and Schmid, M. and Hattingen, E. and Pietsch, T. and Coch, C. and Glas, M.
Lancet 393 (10172): 678-688. 16 February 2019

IDH2 inhibition: another piece to the puzzle.
Bullinger, L.
Blood 133 (7): 625-626. 14 February 2019

Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation.
Frick, M. and Chan, W. and Arends, C.M. and Hablesreiter, R. and Halik, A. and Heuser, M. and Michonneau, D. and Blau, O. and Hoyer, K. and Christen, F. and Galan-Sousa, J. and Noerenberg, D. and Wais, V. and Stadler, M. and Yoshida, K. and Schetelig, J. and Schuler, E. and Thol, F. and Clappier, E. and Christopeit, M. and Ayuk, F. and Bornhäuser, M. and Blau, I.W. and Ogawa, S. and Zemojtel, T. and Gerbitz, A. and Wagner, E.M. and Spriewald, B.M. and Schrezenmeier, H. and Kuchenbauer, F. and Kobbe, G. and Wiesneth, M. and Koldehoff, M. and Socié, G. and Kroeger, N. and Bullinger, L. and Thiede, C. and Damm, F.
Journal of Clinical Oncology 37 (5): 375-385. 10 February 2019

Analysis of the CDK4/6 cell cycle pathway in leiomyosarcomas as a potential target for inhibition by palbociclib.
Böhm, M.J. and Marienfeld, R. and Jäger, D. and Mellert, K. and von Witzleben, A. and Brüderlein, S. and Wittau, M. and von Baer, A. and Schultheiss, M. and Mayer-Steinacker, R. and Rücker, F.G. and Möller, P. and Bullinger, L. and Barth, T.F.E.
Sarcoma 2019 : 3914232. 21 January 2019

2018

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Jacquelin, S. and Straube, J. and Cooper, L. and Vu, T. and Song, A. and Bywater, M. and Baxter, E. and Heidecker, M. and Wackrow, B. and Porter, A. and Ling, V. and Green, J. and Austin, R. and Kazakoff, S. and Waddell, N. and Hesson, L.B. and Pimanda, J.E. and Stegelmann, F. and Bullinger, L. and Döhner, K. and Rampal, R.K. and Heckl, D. and Hill, G.R. and Lane, S.W.
Blood 132 (26): 2707-2721. 27 December 2018

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Döhner, H. and Dolnik, A. and Tang, L. and Seymour, J.F. and Minden, M.D. and Stone, R.M. and Del Castillo, T.B. and Al-Ali, H.K. and Santini, V. and Vyas, P. and Beach, C L. and MacBeth, K.J. and Skikne, B.S. and Songer, S. and Tu, N. and Bullinger, L. and Dombret, H.
Leukemia 32 (12): 2546-2557. December 2018

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.
Zajac, M. and Zaleska, J. and Dolnik, A. and Bullinger, L. and Giannopoulos, K.
British Journal of Haematology 183 (5): 822-825. December 2018

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol, F. and Gabdoulline, R. and Liebich, A. and Klement, P. and Schiller, J. and Kandziora, C. and Hambach, L. and Stadler, M. and Koenecke, C. and Flintrop, M. and Pankratz, M. and Wichmann, M. and Neziri, B. and Büttner, K. and Heida, B. and Klesse, S. and Chaturvedi, A. and Kloos, A. and Göhring, G. and Schlegelberger, B. and Gaidzik, V.I. and Bullinger, L. and Fiedler, W. and Heim, A. and Hamwi, I. and Eder, M. and Krauter, J. and Schlenk, R.F. and Paschka, P. and Döhner, K. and Döhner, H. and Ganser, A. and Heuser, M.
Blood 132 (16): 1703-1713. 18 October 2018

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
L'Abbate, A. and Tolomeo, D. and Cifola, I. and Severgnini, M. and Turchiano, A. and Augello, B. and Squeo, G. and D'Addabbo, P. and Traversa, D. and Daniele, G. and Lonoce, A. and Pafundi, M. and Carella, M. and Palumbo, O. and Dolnik, A. and Muehlematter, D. and Schoumans, J. and Van Roy, N. and De Bellis, G. and Martinelli, G. and Merla, G. and Bullinger, L. and Haferlach, C. and Storlazzi, C.T.
Leukemia 32 (10): 2152-2166. October 2018

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Rudat, S. and Pfaus, A. and Cheng, Y.Y. and Holtmann, J. and Ellegast, J.M. and Bühler, C. and Marcantonio, D.D. and Martinez, E. and Göllner, S. and Wickenhauser, C. and Müller-Tidow, C. and Lutz, C. and Bullinger, L. and Milsom, M.D. and Sykes, S.M. and Fröhling, S. and Scholl, C.
Leukemia 32 (10): 2189-2202. October 2018

Circular RNAs in cancer.
Lux, S. and Bullinger, L.
Advances in Experimental Medicine and Biology 1087 : 215-230. 28 September 2018

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede, S. and Nieborowska-Skorska, M. and Sullivan-Reed, K. and Dasgupta, Y. and Podszywalow-Bartnicka, P. and Le, B.V. and Solecka, M. and Lian, Z. and Belyaeva, E.A. and Nersesyan, A. and Machnicki, M.M. and Toma, M. and Chatain, N. and Rydzanicz, M. and Zhao, H. and Jelinek, J. and Piwocka, K. and Sliwinski, T. and Stoklosa, T. and Ploski, R. and Fischer, T. and Sykes, S.M. and Koschmieder, S. and Bullinger, L. and Valent, P. and Wasik, M.A. and Huang, J. and Skorski, T.
Blood 132 (1): 67-77. 5 July 2018

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Paschka, P. and Schlenk, R.F. and Weber, D. and Benner, A. and Bullinger, L. and Heuser, M. and Gaidzik, V.I. and Thol, F. and Agrawal, M. and Teleanu, V. and Lübbert, M. and Fiedler, W. and Radsak, M. and Krauter, J. and Horst, H.A. and Greil, R. and Mayer, K. and Kündgen, A. and Martens, U. and Heil, G. and Salih, H.R. and Hertenstein, B. and Schwänen, C. and Wulf, G. and Lange, E. and Pfreundschuh, M. and Ringhoffer, M. and Girschikofsky, M. and Heinicke, T. and Kraemer, D. and Göhring, G. and Ganser, A. and Döhner, K. and Döhner, H.
Leukemia 32 (7): 1621-1630. July 2018

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Gozdecka, M. and Meduri, E. and Mazan, M. and Tzelepis, K. and Dudek, M. and Knights, A.J. and Pardo, M. and Yu, L. and Choudhary, J.S. and Metzakopian, E. and Iyer, V. and Yun, H. and Park, N. and Varela, I. and Bautista, R. and Collord, G. and Dovey, O. and Garyfallos, D.A. and De Braekeleer, E. and Kondo, S. and Cooper, J. and Göttgens, B. and Bullinger, L. and Northcott, P.A. and Adams, D. and Vassiliou, G.S. and Huntly, B.J.P.
Nature Genetics 50 (6): 883-894. June 2018

Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl, S.R. and Bullinger, L. and Rücker, F.G.
Expert Review of Hematology 11 (5): 361-371. May 2018

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Mohr, J. and Dash, B.P. and Schnoeder, T.M. and Wolleschak, D. and Herzog, C. and Tubio Santamaria, N. and Weinert, S. and Godavarthy, S. and Zanetti, C. and Naumann, M. and Hartleben, B. and Huber, T.B. and Krause, D.S. and Kähne, T. and Bullinger, L. and Heidel, F.H.
Leukemia 32 (5): 1211-1221. May 2018

MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.
Frech, M. and Teichler, S. and Feld, C. and Bouchard, C. and Berberich, H. and Sorg, K. and Mernberger, M. and Bullinger, L. and Bauer, U.M. and Neubauer, A.
Oncotarget 9 (32): 22423-22435. 27 April 2018

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.
Schneider, E. and Staffas, A. and Röhner, L. and Malmberg, E.D. and Ashouri, A. and Krowiorz, K. and Pochert, N. and Miller, C. and Wei, S.Y. and Arabanian, L. and Buske, C. and Döhner, H. and Bullinger, L. and Fogelstrand, L. and Heuser, M. and Döhner, K. and Xiang, P. and Ruschmann, J. and Petriv, O.I. and Heravi-Moussavi, A. and Hansen, C.L. and Hirst, M. and Humphries, R.K. and Rouhi, A. and Palmqvist, L. and Kuchenbauer, F.
Haematologica 103 (2): 246-255. February 2018

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
Jeck, J. and Kassubek, R. and Coburger, J. and Edenhofer, S. and Schönsteiner, S.S. and Ludolph, A.C. and Schmitz, B. and Engelke, J. and Mayer-Steinacker, R. and Lewerenz, J. and Bullinger, L.
Therapeutic Advances in Neurological Disorders 11 : 1756285617753597. 21 January 2018

Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.
Rücker, F.G. and Dolnik, A. and Blätte, T.J. and Teleanu, V. and Ernst, A. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H. and Döhner, K. and Bullinger, L.
Haematologica 103 (1): e17-e20. January 2018

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik, V.I. and Weber, D. and Paschka, P. and Kaumanns, A. and Krieger, S. and Corbacioglu, A. and Krönke, J. and Kapp-Schwoerer, S. and Krämer, D. and Horst, H.A. and Schmidt-Wolf, I. and Held, G. and Kündgen, A. and Ringhoffer, M. and Götze, K. and Kindler, T. and Fiedler, W. and Wattad, M. and Schlenk, R.F. and Bullinger, L. and Teleanu, V. and Schlegelberger, B. and Thol, F. and Heuser, M. and Ganser, A. and Döhner, H. and Döhner, K.
Leukemia 32 (1): 30-37. January 2018

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Wais, V. and Kündgen, L. and Bohl, S.R. and von Harsdorf, S. and Schlenk, R.F. and Döhner, K. and Teleanu, V. and Bullinger, L. and Nguyen, T.M. and Drognitz, K. and Moulin, J.C. and Binnenhei, M. and Bentz, M. and Döhner, H. and Bunjes, D. and Kuchenbauer, F. and Ringhoffer, M.
Bone marrow transplantation 53 (1): 94-96. January 2018

The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.
Nickel, K. and Renovanz, M. and König, J. and Stöckelmaier, L. and Hickmann, A.K. and Nadji-Ohl, M. and Engelke, J. and Weimann, E. and Freudenstein, D. and Ganslandt, O. and Bullinger, L. and Wirtz, C.R. and Coburger, J.
Neurosurgical Review 41 (1): 207-219. January 2018

2017

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
Nagel, G. and Weber, D. and Fromm, E. and Erhardt, S. and Lübbert, M. and Fiedler, W. and Kindler, T. and Krauter, J. and Brossart, P. and Kündgen, A. and Salih, H.R. and Westermann, J. and Wulf, G. and Hertenstein, B. and Wattad, M. and Götze, K. and Kraemer, D. and Heinicke, T. and Girschikofsky, M. and Derigs, H.G. and Horst, H.A. and Rudolph, C. and Heuser, M. and Göhring, G. and Teleanu, V. and Bullinger, L. and Thol, F. and Gaidzik, V.I. and Paschka, P. and Döhner, K. and Ganser, A. and Döhner, H. and Schlenk, R.F.
Annals of Hematology 96 (12): 1993-2003. 1 December 2017

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
Greiner, J. and Hofmann, S. and Schmitt, M. and Götz, M. and Wiesneth, M. and Schrezenmeier, H. and Bunjes, D. and Döhner, H. and Bullinger, L.
Haematologica 102 (12): e499-e501. December 2017

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.
Hirsch, S. and Blätte, T.J. and Grasedieck, S. and Cocciardi, S. and Rouhi, A. and Jongen-Lavrencic, M. and Paschka, P. and Krönke, J. and Gaidzik, V.I. and Döhner, H. and Schlenk, R.F. and Kuchenbauer, F. and Döhner, K. and Dolnik, A. and Bullinger, L.
Haematologica 102 (12): 2039-2047. December 2017

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel, S. and Falcone, M. and Kneisel, N. and Hansson, J. and Wang, W. and Lutz, C. and Bullinger, L. and Poschet, G. and Nonnenmacher, Y. and Barnert, A. and Bahr, C. and Zeisberger, P. and Przybylla, A. and Sohn, M. and Tönjes, M. and Erez, A. and Adler, L. and Jensen, P. and Scholl, C. and Fröhling, S. and Cocciardi, S. and Wuchter, P. and Thiede, C. and Flörcken, A. and Westermann, J. and Ehninger, G. and Lichter, P. and Hiller, K. and Hell, R. and Herrmann, C. and Ho, A.D. and Krijgsveld, J. and Radlwimmer, B. and Trumpp, A.
Nature 551 (7680): 384-388. 16 November 2017

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.
Zajac, M. and Dolnik, A. and Stasiak, G. and Zaleska, J. and Kielbus, M. and Czapinski, J. and Schunn, M. and Correa, S.C. and Glodkowska-Mrowka, E. and Sundaram, R.C. and Jankowska-Lecka, O. and Schlenk, R.F. and Döhner, H. and Döhner, K. and Stepulak, A. and Bullinger, L. and Giannopoulos, K.
Oncotarget 8 (56): 95163-95175. 10 November 2017

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.
Herzig, J.K. and Bullinger, L. and Tasdogan, A. and Zimmermann, P. and Schlegel, M. and Teleanu, V. and Weber, D. and Rücker, F.G. and Paschka, P. and Dolnik, A. and Schneider, E. and Kuchenbauer, F. and Heidel, F.H. and Buske, C. and Döhner, H. and Döhner, K. and Gaidzik, V.I.
Oncotarget 8 (56): 95038-95053. 10 November 2017

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel, V.N. and Giaimo, B.D. and Schwarz, P. and Soller, K. and Vas, V. and Bartkuhn, M. and Blätte, T.J. and Döhner, K. and Bullinger, L. and Borggrefe, T. and Geiger, H. and Oswald, F.
Leukemia 31 (11): 2491-2502. November 2017

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Yalcin, A. and Kovarbasic, M. and Wehrle, J. and Claus, R. and Becker, H. and Abdelkarim, M. and Gaidzik, V.I. and Schmidts, A. and Wäsch, R. and Pahl, H.L. and Döhner, K. and Bullinger, L. and Duyster, J. and Lübbert, M. and Hackanson, B.
Experimental Hematology 55 : 76-85. November 2017

Partitioned learning of deep Boltzmann machines for SNP data.
Hess, M. and Lenz, S. and Blätte, T.J. and Bullinger, L. and Binder, H.
Bioinformatics 33 (20): 3173-3180. October 2017

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl, S.R. and Dolnik, A. and Jensen, T. and Lang, K.M. and Hackanson, B. and Gaidzik, V.I. and Paschka, P. and Knudsen, S. and Döhner, K. and Döhner, H. and Claus, R. and Lübbert, M. and Bullinger, L.
Leukemia & Lymphoma 58 (9): 2264-2267. 2 September 2017

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Nieborowska-Skorska, M. and Sullivan, K. and Dasgupta, Y. and Podszywalow-Bartnicka, P. and Hoser, G. and Maifrede, S. and Martinez, E. and Di Marcantonio, D. and Bolton-Gillespie, E. and Cramer-Morales, K. and Lee, J. and Li, M. and Slupianek, A. and Gritsyuk, D. and Cerny-Reiterer, S. and Seferynska, I. and Stoklosa, T. and Bullinger, L. and Zhao, H. and Gorbunova, V. and Piwocka, K. and Valent, P. and Civin, C.I. and Muschen, M. and Dick, J.E. and Wang, J.C. and Bhatia, S. and Bhatia, R. and Eppert, K. and Minden, M.D. and Sykes, S.M. and Skorski, T.
Journal of Clinical Investigation 127 (6): 2392-2406. 1 June 2017

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol, F. and Klesse, S. and Köhler, L. and Gabdoulline, R. and Kloos, A. and Liebich, A. and Wichmann, M. and Chaturvedi, A. and Fabisch, J. and Gaidzik, V.I. and Paschka, P. and Bullinger, L. and Bug, G. and Serve, H. and Göhring, G. and Schlegelberger, B. and Lübbert, M. and Kirchner, H. and Wattad, M. and Kraemer, D. and Hertenstein, B. and Heil, G. and Fiedler, W. and Krauter, J. and Schlenk, R.F. and Döhner, K. and Döhner, H. and Ganser, A. and Heuser, M.
Leukemia 31 (6): 1286-1295. June 2017

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke, J. and Kuchenbauer, F. and Kull, M. and Teleanu, V. and Bullinger, L. and Bunjes, D. and Greiner, A. and Kolmus, S. and Köpff, S. and Schreder, M. and Mügge, L.O. and Straka, C. and Engelhardt, M. and Döhner, H. and Einsele, H. and Bassermann, F. and Bargou, R. and Knop, S. and Langer, C.
Leukemia 31 (6): 1363-1367. June 2017

Novel treatment options in head and neck cancer.
Schuler, P.J. and Laban, S. and Doescher, J. and Bullinger, L. and Hoffmann, T.K.
Oncology Research and Treatment 40 (6): 342-346. June 2017

Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life.
Stöckelmaier, L. and Renovanz, M. and König, J. and Nickel, K. and Hickmann, A.K. and Mayer-Steinacker, R. and Nadji-Ohl, M. and Ganslandt, O. and Bullinger, L. and Wirtz, C.R. and Coburger, J.
World Neurosurgery 102 : 383-399. June 2017

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Hiller, J.K. and Schmoor, C. and Gaidzik, V.I. and Schmidt-Salzmann, C. and Yalcin, A. and Abdelkarim, M. and Blagitko-Dorfs, N. and Döhner, K. and Bullinger, L. and Duyster, J. and Lübbert, M. and Hackanson, B.
Annals of Hematology 96 (4): 559-565. April 2017

Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.
Kassubek, R. and Bullinger, L. and Kassubek, J. and Dreyhaupt, J. and Ludolph, A.C. and Althaus, K. and Lewerenz, J.
Journal of Neurology 264 (4): 781-791. April 2017

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Jahn, N. and Agrawal, M. and Bullinger, L. and Weber, D. and Corbacioglu, A. and Gaidzik, V.I. and Schmalbrock, L. and Thol, F. and Heuser, M. and Krauter, J. and Göhring, G. and Kündgen, A. and Fiedler, W. and Wattad, M. and Held, G. and Köhne, C.H. and Horst, H.A. and Lübbert, M. and Ganser, A. and Schlenk, R.F. and Döhner, H. and Döhner, K. and Paschka, P.
Leukemia 31 (4): 1012-1015. April 2017

Genomics of acute myeloid leukemia diagnosis and pathways.
Bullinger, L. and Döhner, K. and Döhner, H.
Journal of Clinical Oncology 35 (9): 934-946. 20 March 2017

Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Gerstung, M. and Papaemmanuil, E. and Martincorena, I. and Bullinger, L. and Gaidzik, V.I. and Paschka, P. and Heuser, M. and Thol, F. and Bolli, N. and Ganly, P. and Ganser, A. and McDermott, U. and Döhner, K. and Schlenk, R.F. and Döhner, H. and Campbell, P.J.
Nature Genetics 49 (3): 332-340. March 2017

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Qu, Y. and Siggens, L. and Cordeddu, L. and Gaidzik, V.I. and Karlsson, K. and Bullinger, L. and Döhner, K. and Ekwall, K. and Lehmann, S. and Lennartsson, A.
Blood 129 (7): e13-e25. 16 February 2017

Response evaluation in head and neck oncology: definition and prediction.
Hoffmann, T.K. and Schuler, P.J. and Laban, S. and Grässlin, R. and Beer, M. and Beer, A.J. and Friebe-Hoffmann, U. and Bullinger, L. and Möller, P. and Wiegel, T.
ORL 79 (1-2): 14-23. February 2017

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi, A. and Miller, C. and Grasedieck, S. and Reinhart, S. and Stolze, B. and Döhner, H. and Kuchenbauer, F. and Bullinger, L. and Fröhling, S. and Scholl, C.
Oncotarget 8 (5): 7678-7690. 31 January 2017

2016

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia.
Krowiorz, K. and Ruschmann, J. and Lai, C. and Ngom, M. and Maetzig, T. and Martins, V. and Scheffold, A. and Schneider, E. and Pochert, N. and Miller, C. and Palmqvist, L. and Staffas, A. and Mulaw, M. and Bohl, S.R. and Buske, C. and Heuser, M. and Kraus, J. and O'Neill, K. and Hansen, C.L. and Petriv, O.I. and Kestler, H. and Döhner, H. and Bullinger, L. and Döhner, K. and Humphries, R.K. and Rouhi, A. and Kuchenbauer, F.
Blood Cancer Journal 6 (12): e508. December 2016

The genomic landscape of core-binding factor acute myeloid leukemias.
Faber, Z.J. and Chen, X. and Gedman, A.L. and Boggs, K. and Cheng, J. and Ma, J. and Radtke, I. and Chao, J.R. and Walsh, M.P. and Song, G. and Andersson, A.K. and Dang, J. and Dong, L. and Liu, Y. and Huether, R. and Cai, Z. and Mulder, H. and Wu, G. and Edmonson, M. and Rusch, M. and Qu, C. and Li, Y. and Vadodaria, B. and Wang, J. and Hedlund, E. and Cao, X. and Yergeau, D. and Nakitandwe, J. and Pounds, S.B. and Shurtleff, S. and Fulton, R.S. and Fulton, L.L. and Easton, J. and Parganas, E. and Pui, C.H. and Rubnitz, J.E. and Ding, L. and Mardis, E.R. and Wilson, R.K. and Gruber, T.A. and Mullighan, C.G. and Schlenk, R.F. and Paschka, P. and Döhner, K. and Döhner, H. and Bullinger, L. and Zhang, J. and Klco, J.M. and Downing, J.R.
Nature Genetics 48 (12): 1551-1556. December 2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis, F. and Corbacioglu, A. and Gaidzik, V.I. and Paschka, P. and Weber, D. and Bullinger, L. and Heuser, M. and Ganser, A. and Thol, F. and Schlegelberger, B. and Göhring, G. and Köhne, C.H. and Germing, U. and Brossart, P. and Horst, H.A. and Haase, D. and Götze, K. and Ringhoffer, M. and Fiedler, W. and Nachbaur, D. and Kindler, T. and Held, G. and Lübbert, M. and Wattad, M. and Salih, H.R. and Krauter, J. and Döhner, H. and Schlenk, R.F. and Döhner, K.
Leukemia 30 (11): 2248-2250. November 2016

MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.
Shivarov, V. and Dolnik, A. and Lang, K.M. and Krönke, J. and Kuchenbauer, F. and Paschka, P. and Gaidzik, V.I. and Döhner, H. and Schlenk, R.F. and Döhner, K. and Bullinger, L.
Haematologica 101 (11): e454-e456. November 2016

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik, V.I. and Teleanu, V. and Papaemmanuil, E. and Weber, D. and Paschka, P. and Hahn, J. and Wallrabenstein, T. and Kolbinger, B. and Köhne, C.H. and Horst, H.A. and Brossart, P. and Held, G. and Kündgen, A. and Ringhoffer, M. and Götze, K. and Rummel, M. and Gerstung, M. and Campbell, P. and Kraus, J.M. and Kestler, H.A. and Thol, F. and Heuser, M. and Schlegelberger, B. and Ganser, A. and Bullinger, L. and Schlenk, R.F. and Döhner, K. and Döhner, H.
Leukemia 30 (11): 2160-2168. November 2016

Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information.
Hieke, S. and Benner, A. and Schlenl, R.F. and Schumacher, M. and Bullinger, L. and Binder, H.
BMC Bioinformatics 17 (1): 327. 30 August 2016

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
Lueck, S.C. and Russ, A.C. and Botzenhardt, U. and Schlenk, R.F. and Zobel, K. and Deshayes, K. and Vucic, D. and Döhner, H. and Döhner, K. and Fulda, S. and Bullinger, L.
Oncotarget 7 (31): 49539-49551. 2 August 2016

GPR56 contributes to the development of acute myeloid leukemia in mice.
Daria, D. and Kirsten, N. and Muranyi, A. and Mulaw, M. and Ihme, S. and Kechter, A. and Hollnagel, M. and Bullinger, L. and Döhner, K. and Döhner, H. and Feuring-Buske, M. and Buske, C.
Leukemia 30 (8): 1734-1741. August 2016

Genomic classification and prognosis in acute myeloid leukemia.
Papaemmanuil, E. and Gerstung, M. and Bullinger, L. and Gaidzik, V.I. and Paschka, P. and Roberts, N.D. and Potter, N.E. and Heuser, M. and Thol, F. and Bolli, N. and Gundem, G. and Van Loo, P. and Martincorena, I. and Ganly, P. and Mudie, L. and McLaren, S. and O'Meara, S. and Raine, K. and Jones, D.R. and Teague, J.W. and Butler, A.P. and Greaves, M.F. and Ganser, A. and Döhner, K. and Schlenk, R.F. and Döhner, H. and Campbell, P.J.
New England Journal of Medicine 374 (23): 2209-2221. 12 July 2016

Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Rücker, F.G. and Lang, K.M. and Fütterer, M. and Komarica, V. and Schmid, M. and Döhner, H. and Schlenk, R.F. and Döhner, K. and Knudsen, S. and Bullinger, L.
Epigenetics 11 (7): 517-525. 2 July 2016

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Li, S. and Garrett-Bakelman, F.E. and Chung, S.S. and Sanders, M.A. and Hricik, T. and Rapaport, F. and Patel, J. and Dillon, R. and Vijay, P. and Brown, A.L. and Perl, A.E. and Cannon, J. and Bullinger, L. and Luger, S. and Becker, M. and Lewis, I.D. and To, L.B. and Delwel, R. and Löwenberg, B. and Döhner, H. and Döhner, K. and Guzman, M.L. and Hassane, D.C. and Roboz, G.J. and Grimwade, D. and Valk, P.J.M. and D'Andrea, R.J. and Carroll, M. and Park, C.Y. and Neuberg, D. and Levine, R. and Melnick, A.M. and Mason, C.E.
Nature Medicine 22 (7): 792-9. July 2016

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.
Bohl, S. and von Harsdorf, S. and Mulaw, M. and Hofmann, S. and Babiak, A. and Maier, C.P. and Schnell, J. and Hütter-Krönke, L.M. and Scholl, K. and Wais, V. and Schlenk, R.F. and Bullinger, L. and Ringhoffer, M. and Döhner, H. and Bunjes, D. and Bommer, M. and Kuchenbauer, F.
Bone Marrow Transplantation 51 (7): 994-996. July 2016

GiANT: gene set uncertainty in enrichment analysis.
Schmid, F. and Schmid, M. and Müssel, C. and Sträng, J.E. and Buske, C. and Bullinger, L. and Kraus, J.M. and Kestler, H.A.
Bioinformatics 32 (12): 1891-1894. 15 June 2016

Low-grade glioma surgery in intraoperative magnetic resonance imaging: Results of a multicenter retrospective assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging.
Coburger, J. and Merkel, A. and Scherer, M. and Schwartz, F. and Gessler, F. and Roder, C. and Pala, A. and König, R. and Bullinger, L. and Nagel, G. and Jungk, C. and Bisdas, S. and Nabavi, A. and Ganslandt, O. and Seifert, V. and Tatagiba, M. and Senft, C. and Mehdorn, M. and Unterberg, A.W. and Rössler, K. and Wirtz, C.R.
Neurosurgery 78 (6): 775-86. June 2016

Identifying prognostic SNPs in clinical cohorts: complementing univariate ynalyses by resampling and multivariable modeling.
Hieke, S. and Benner, A. and Schlenk, R.F. and Schumacher, M. and Bullinger, L. and Binder, H.
PLoS ONE 11 (5): e0155226. May 2016

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Arreba-Tutusaus, P. and Mack, T.S. and Bullinger, L. and Schnöder, T.M. and Polanetzki, A. and Weinert, S. and Ballaschk, A. and Wang, Z. and Deshpande, A.J. and Armstrong, S.A. and Döhner, K. and Fischer, T. and Heidel, F.H.
Leukemia 30 (5): 1220-1225. May 2016

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Nowek, K. and Sun, S.M. and Dijkstra, M.K. and Bullinger, L. and Döhner, H. and Erkeland, S.J. and Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (2): 303-9. February 2016

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Nowek, K. and Sun, S.M. and Bullinger, L. and Bindels, E.M.J. and Exalto, C. and Dijkstra, M.K. and van Lom, K. and Döhner, H. and Erkeland, S.J. and Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (1): 229-37. January 2016

2015

Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel, D. and Schnaiter, A. and Dodier, D. and Jovanovic, M. and Gerhardinger, A. and Idler, I. and Mertens, D. and Bullinger, L. and Stilgenbauer, S. and Fulda, S.
International Journal of Cancer 137 (12): 2959-2970. 15 December 2015

Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
Schneider, V. and Zhang, L. and Rojewski, M. and Fekete, N. and Schrezenmeier, H. and Erle, A. and Bullinger, L. and Hofmann, S. and Götz, M. and Döhner, K. and Ihme, S. and Döhner, H. and Buske, C. and Feuring-Buske, M. and Greiner, J.
International Journal of Cancer 137 (9): 2083-2092. 1 November 2015

Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana, K. and Wang, J. and Renneville, A. and Bödör, C. and Hills, R. and Loveday, C. and Savic, A. and Van Delft, F.W. and Treleaven, J. and Georgiades, P. and Uglow, E. and Asou, N. and Uike, N. and Debeljak, M. and Jazbec, J. and Ancliff, P. and Gale, R. and Thomas, X. and Mialou, V. and Döhner, K. and Bullinger, L. and Mueller, B. and Pabst, T. and Stelljes, M. and Schlegelberger, B. and Wozniak, E. and Iqbal, S. and Okosun, J. and Araf, S. and Frank, A.K. and Lauridsen, F.B. and Porse, B. and Nerlov, C. and Owen, C. and Dokal, I. and Gribben, J. and Smith, M. and Preudhomme, C. and Chelala, C. and Cavenagh, J. and Fitzgibbon, J.
Blood 126 (10): 1214-1223. 3 September 2015

Immuntherapie von Kopf-Hals-Karzinomen - Highlights des ASCO-Kongresses 2015 [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
Laban, S. and Doescher, J. and Schuler, P.J. and Bullinger, L. and Brunner, C. and Veit, J.A. and Hoffmann, T.K.
HNO 63 (9): 612-619. September 2015

Cellular origin of prognostic chromosomal aberrations in AML patients.
Mora-Jensen, H. and Jendholm, J. and Rapin, N. and Andersen, M.K. and Roug, A.S. and Bagger, F.O. and Bullinger, L. and Winther, O. and Borregaard, N. and Porse, B.T. and Theilgaard-Mönch, K.
Leukemia 29 (8): 1785-9. August 2015

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm, K.M. and Langer, C. and Monge, J. and Bruins, L. and Zhu, Y.X. and Shi, C.X. and Jedlowski, P. and Egan, J.B. and Ojha, J. and Bullinger, L. and Kull, M. and Ahmann, G. and Rasche, L. and Knop, S. and Fonseca, R. and Einsele, H. and Stewart, A.K. and Braggio, E.
Annals of Hematology 94 (7): 1205-1211. July 2015

Epo-induced erythroid maturation is dependent on Plcγ1 signaling.
Schnöder, T.M. and Arreba-Tutusaus, P. and Griehl, I. and Bullinger, L. and Buschbeck, M. and Lane, S.W. and Döhner, K. and Plass, C. and Lipka, D.B. and Heidel, F.H. and Fischer, T.
Cell Death and Differentiation 22 (6): 974-985. June 2015

TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer, A. and Jakobsen, J.S. and Ohlsson, E. and Rapin, N. and Waage, J. and Billing, M. and Bullinger, L. and Karlsson, S. and Porse, B.T.
Leukemia 29 (5): 1018-1031. May 2015

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka, P. and Schlenk, R.F. and Gaidzik, V.I. and Herzig, J.K. and Aulitzky, T. and Bullinger, L. and Späth, D. and Teleanu, V. and Kündgen, A. and Köhne, C.H. and Brossart, P. and Held, G. and Horst, H.A. and Ringhoffer, M. and Götze, K. and Nachbaur, D. and Kindler, T. and Heuser, M. and Thol, F. and Ganser, A. and Döhner, H. and Döhner, K.
Haematologica 100 (3): 324-330. March 2015

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm, K.M. and Langer, C. and Monge, J. and Bruins, L. and Egan, J.B. and Zhu, Y.X. and Shi, C.X. and Jedlowski, P. and Schmidt, J. and Ojha, J. and Bullinger, L. and Liebisch, P. and Kull, M. and Champion, M.D. and Van Wier, S. and Ahmann, G. and Rasche, L. and Knop, S. and Fonseca, R. and Einsele, H. and Stewart, A.K. and Braggio, E.
British Journal of Haematology 168 (4): 507-510. February 2015

2014

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Bruedigam, C. and Bagger, F.O. and Heidel, F.H. and Paine Kuhn, C. and Guignes, S. and Song, A. and Austin, R. and Vu, T. and Lee, E. and Riyat, S. and Moore, A.S. and Lock, R.B. and Bullinger, L. and Hill, G.R. and Armstrong, S.A. and Williams, D.A. and Lane, S.W.
Cell Stem Cell 15 (6): 775-90. 4 December 2014

Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation.
Schlenk, R.F. and Kayser, S. and Bullinger, L. and Kobbe, G. and Casper, J. and Ringhoffer, M. and Held, G. and Brossart, P. and Lübbert, M. and Salih, H.R. and Kindler, T. and Horst, H.A. and Wulf, G. and Nachbaur, D. and Götze, K. and Lamparter, A. and Paschka, P. and Gaidzik, V.I. and Teleanu, V. and Späth, D. and Benner, A. and Krauter, J. and Ganser, A. and Döhner, H. and Döhner, K.
Blood 124 (23): 3441-3449. 27 November 2014

A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples.
Risueño, A. and Roson-Burgo, B. and Dolnik, A. and Hernandez-Rivas, J.M. and Bullinger, L. and De Las Rivas, J.
BMC Genomics 15 : 879. 8 October 2014

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.
Feurstein, S. and Rücker, F.G. and Bullinger, L. and Hofmann, W. and Manukjan, G. and Göhring, G. and Lehmann, U. and Heuser, M. and Ganser, A. and Döhner, K. and Schlegelberger, B. and Steinemann, D.
BMC Genomics 15 : 784. 11 September 2014

2013

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.
Dickson, G.J. and Liberante, F.G. and Kettyle, L.M. and O'Hagan, K.A. and Finnegan, D.P.J. and Bullinger, L. and Geerts, D. and McMullin, M.F. and Lappin, T.R.J. and Mills, K.I. and Thompson, A.
Haematologica 98 (8): 1216-25. August 2013